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Abstract 
 
Alzheimer’s disease (AD) is the most common cause of dementia. 
Neuroinflammation is one of the key pathological features of AD, suggesting 
microglia, the major immune cell type in the brain, may play an important role 
in AD development. Furthermore, GWAS studies have found rare variants in 
immune-related gene TREM2 that increase AD risk by ~2-3 fold. TREM2 
therefore seems critically implicated in the microglial functions in AD 
progression, and targeting its role may yield protective agents for AD. 
Although several recent studies have begun to shed light on the importance of 
microglia in dementia and the cellular function of TREM2, at time this thesis 
was started there was very little known about TREM2. 
 
To investigate microglia and TREM2 implications in AD, first I characterized 
the microglial response in relation to different stages of pathology 
development of AD via molecular biology and immunohistochemistry in brain 
samples of mice modeling either abnormal amyloid beta accumulation 
(APPSwe/PS1M146V transgenic mice) or tauopathy (TAUP301L transgenic 
mice). Both mouse models showed robust microglial activation, as manifested 
by expansion of microglial population along with pathology progression in the 
brain and up-regulation of microglial genes. I subsequently established an in 
vitro primary microglial model with acute Trem2 knock-down to study the role 
of TREM2 loss-of-function in microglia. Endogenous Trem2 expression in 
primary microglia was largely inhibited with pro-inflammatory stimulation such 
as LPS but up-regulated with anti-inflammatory stimuli such as Interleukin-4. 
Trem2 knock-down resulted in significant gene expression changes in the 
microglia, and also impaired anti-inflammatory responses and phagocytosis. 
The results suggest decreased expression and/or function of TREM2, due to 
accumulated inflammatory stimuli in the brain or loss-of-function variants of 
TREM2, may shift the transcriptional and functional balance of microglia away 
from anti-inflammatory and phagocytic properties towards pro-inflammatory 
properties, which might contribute to AD progression.  
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Chapter 1  
Introduction 
 
 
Alzheimer’s disease 
 
Dementia refers to a category of diseases resulting in memory loss and 
cognitive decline, which mainly affects the elderly. Increasing life expectancy 
has led to a dramatic increase in the incidence of dementia. Alzheimer's 
disease (AD) is the most common cause of dementia, accounting for 
proximately 60-70% of cases (World Health Organization, 2017). It has gained 
a huge amount of scientific interest and also public concern, considering that 
the exact pathogenesis mechanism is still not clear and there is neither 
effective methods for early diagnosis nor a cure for this complex multifactorial 
syndrome. As the number of the AD cases is expected to continue increasing, 
both the huge economic burden on society and the enormous emotional pain 
of the patients and their families require more intensive research for further 
understanding of the disease mechanisms and effective preventative / 
curative methods.  
 
Apart from progressive degeneration of multiple neuronal populations in the 
brain, AD is characterized by two major pathological hallmarks: amyloid 
plaques and neurofibrillary tangles. Amyloid plaques are mainly formed by 
extracellular deposition of aggregated amyloid beta (Aβ) peptides (products of 
intramembranous proteolysis of amyloid precursor protein (APP)). 
Neurofibrillary tangles are generated by intracellular aggregation of 
abnormally hyperphosphorylated microtubule-associated protein tau. In 
addition, neuroinflammation is another important characteristic in the AD 
brain, in terms of reactive microglia, astrocytes and various inflammatory 
components associated with AD pathology. 
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What do we know about the mechanisms underlying AD? 
 
Since its first description in the early 20th century, AD has been studied 
intensely for its underlying mechanisms by neuroscientists and neurologists. 
Although the final conclusion has not been reached, accumulated research 
has led to a few hypotheses trying to reveal how the disease occurs, of which 
the predominant one is the amyloid cascade hypothesis, referring to an initial 
and central role of Aβ dysregulated metabolism in AD pathogenesis. It was 
first established over 25 years ago (Hardy and Allsop, 1991; Hardy and 
Higgins, 1992; Selkoe, 1991), which was prompted by the revelation and 
genetic location of Aβ peptide from senile plaques and the findings of familial-
AD–causative mutations in genes involved in Aβ production. More and more 
evidence since then has accumulated to support and further develop the 
amyloid hypothesis, and formed the basis for our current understanding of AD 
pathogenesis.  
 
Research into APP and presenilins (the active core of γ-secretase) has 
provided key mechanistic discoveries on Aβ production. In brief, APP is a 
constitutive transmembrane protein that can routinely undergo differential 
pathways of progressive proteolysis to produce various products. Aβ peptides 
of different length are generated via an initial cleavage at the APP extracelluar 
domain by β-secretase that is followed by multiple sequential γ-secretase 
cleavages at the intramembrane domain. Released Aβ peptides aggregate 
and deposit in the extracellular space, which constitute the major component 
of Aβ plaques. The longer the Aβ peptide, the more hydrophobic and more 
aggregating it is. In the case of familial AD, mutations in APP or presenilin 
genes affect APP processing, resulting in either elevated total Aβ generation 
or shifted Aβ production towards longer and more toxic species (Benilova et 
al., 2012; Chavez-Gutierrez et al., 2012; Goate et al., 1991; Kretner et al., 
2016; Levy-Lahad et al., 1995; Mullan et al., 1992; Rogaev et al., 1995; 
Sherrington et al., 1995; Zhou et al., 2011). In these cases Aβ dysregulated 
production is the causative factor of the disease. Although the familial subtype 
only constitutes a very small percentage of the total AD population (<5%), it 
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still suggests that Aβ abnormality can initiate the full spectrum of AD 
pathology, including tau tangles and neuronal death.  
 
In the case of the more common sporadic form of AD, despite its exact cause 
not being defined, abnormal Aβ metabolism, e.g. disability in efficient 
clearance of Aβ, is considered to be an early causative event in AD 
development. In particular, genetics has identified several gene variants 
associated with sporadic AD risk, which delineates extra biological processes 
contributing to AD progression. Further research into these molecules has 
revealed an important role in the Aβ homeostatic mechanisms. The strongest 
common AD risk factor is the APOEε4 allele (Corder et al., 1993). It was 
suggested in AD mouse models that ApoE-ε4 expression induced attenuated 
soluble Aβ clearance and more severe Aβ deposition in the brain compared to 
ε3 and ε2 isoforms (Castellano et al., 2011; Holtzman et al., 2000). Other AD-
associated risk factors such as SORL1 (Caglayan et al., 2012; Lambert et al., 
2013; Pottier et al., 2012; Rogaeva et al., 2007) and ABCA7 (Chan et al., 
2008; Cuyvers et al., 2015; Kim et al., 2013; Meurs et al., 2012; Steinberg et 
al., 2015) were also found to regulate the APP amyloidogenic processing 
pathway or Aβ clearance from the brain. Moreover, given that microgliosis 
associated with Aβ deposition is an important pathological characteristics in 
AD, immune-related genes have more recently found to be AD risk 
associated, such as CD33 (Hollingworth et al., 2011; Naj et al., 2011), TREM2 
(Guerreiro et al., 2013b; Jonsson et al., 2013) PLCG2 and ABI3 (Sims et al., 
2017), indicating that the innate immune response, especially microglial 
dysregulation (discussed below) may contribute to AD pathogenesis via over- 
or less sufficient reaction in response to Aβ build-up.     
 
Despite the strongly addressed central initial role of Aβ in AD pathogenesis 
and also the observed neuro-/synapto- toxicity of Aβ in laboratory studies (Jin 
et al., 2011; Shrestha et al., 2006; Snyder et al., 2005; Townsend et al., 2006; 
Walsh et al., 2002), it is still worth noting that Aβ deposition does not seem to 
directly associate with eventual neurodegeneration of AD. A lot of researchers 
have reported that the cognitive decline or the neurodegeneration in AD 
patients did not correlate well with the increase of Aβ deposition in the brain, 
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while the disease severity did strongly correlate with the neurofibrillary tangle 
load and the neuronal/synaptic loss (Arriagada et al., 1992; Giannakopoulos 
et al., 2003; Gomez-Isla et al., 1997; Gomez-Isla et al., 1996; Terry et al., 
1991).  Furthermore, there is more than one report showing non-demented 
elderly cases with comparable plaque burden in the brain to AD patients 
(Aizenstein et al., 2008; Katzman et al., 1988). Also, transgenic mouse 
models overexpressing familial-AD-causative mutations in APP with or without 
PSEN1 show lack of neurofibrillary tangle formation and neuronal loss even at 
very late stages with enormous Aβ plaque deposition (Gotz et al., 2004). 
Collectively, the precise contribution of Aβ to the full development of AD, e.g. 
how it associates with subsequent disease processes, particularly tau tangles 
and neuroinflammatory processes, and whether it drives and/or cooperates 
with other biological processes to eventually lead to neurodegeneration, still 
need to be further clarified. Moreover, since Aβ toxicity studies suggest that 
the small soluble oligomers are the major neurotoxic species rather than the 
plaques (Selkoe, 2008; Townsend et al., 2006; Walsh et al., 2002; Walsh and 
Selkoe, 2007), it has brought about the idea that packing of Aβ oligomers into 
plaques could represent a type of protective mechanism to remove the more 
toxic species, and more importantly, any other biological processes, such as 
reactivated microglia and astrocytes, contributing to this mechanism or 
altering the plaque kinetics could potentially be involved in AD pathogenesis. 
Of various candidates, the innate immune system, especially the microglia are 
one of the earliest and most important components reacting to changed brain 
homeostasis, suggesting there are critical in the process of initial Aβ build up, 
Aβ-triggered subsequent events, and/or the association between neuronal 
loss and Aβ/tau pathology.  
 
 
Microglia  
 
Microglia, constituting ~10% of the total glial population in healthy adult brain, 
are the key immune cell type in the brain parenchyma. Microglia, together with 
meningeal, choroid plexus and perivascular macrophages, compromise the 
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brain myeloid cell population that plays an important role in the CNS immune 
response and homeostasis maintenance.  
 
 
Physiology of microglia  
 
Since first description by Pío del Río Hortega in the early 20th century, the 
origin of microglia had been controversial for many years until recently fate-
mapping studies have revealed that microglia are derived from prenatal 
precursor cells in the yolk sac, which invade the CNS during embryogenesis 
(Ginhoux et al., 2010; Schulz et al., 2012). Further research added more to 
our understanding of microglia development.  The source of microglia is found 
to be a population of CD45- c-kit+ erythromyeloid precursor cells in the yolk 
sac; these cells undergo PU.1- and IRF8- dependent development 
characterized by down-regulation of c-kit and up-regulation of F4/80 and 
CX3CR1, and become the only progenitors of microglia that migrate, 
differentiate, proliferate, and distribute across the developing CNS (Kierdorf et 
al., 2013).  
 
Microglia in the developing brain bear distinct morphological and 
transcriptional characteristics from those in the mature healthy brain (Kierdorf 
et al., 2013; Matcovitch-Natan et al., 2016), which is not surprising as they not 
only undergo terminal differentiation in the CNS environment but also exhibit 
functional phenotypes adapted to neural maturation. One of the most 
important functions of microglia in the developmental brain is the synaptic 
pruning process. It has been found microglia actively engulf synapses and 
promote maturation of brain circuitry in the developing brain, mainly through 
the classical complement cascade of which the major components are highly 
expressed by microglia during postnatal periods (Paolicelli et al., 2011; 
Schafer et al., 2012; Stevens et al., 2007).  
 
In the mature, healthy brain, microglia are found in a ‘resting’ state with a 
typical ramified morphology (a small soma and fine branching processes) and 
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relatively low expression of macrophage-function-related molecules. However, 
increasing evidence suggests that resting microglia exhibit a surveillance 
state in the healthy mature brain rather than just resting (Hanisch and 
Kettenmann, 2007). Studies using time-lapse in vivo two-photon microscopy 
have revealed that the ‘resting’ microglia keep scanning their territories by 
transient and frequent process extension and retraction, and make rapid 
contacts with nearby neurons, glia, and blood vessels (Davalos et al., 2005; Li 
et al., 2012; Nimmerjahn et al., 2005; Wake et al., 2009). Through this kind of 
dynamics microglia may rapidly detect and remove even tiny micro-damage 
without full microglial activation; besides, ‘resting’ microglia may also play a 
role in constitutively monitoring neuronal synaptic activity. It is supported by 
the finding of frequent purinoreceptor-signaling-dependent physical 
interactions between ‘resting’ microglial processes and neuronal synaptic 
elements, which preferentially occurs on neurons of higher activities (Davalos 
et al., 2005; Eyo et al., 2015; Li et al., 2012; Tremblay et al., 2010; Wake et 
al., 2009). Recently, induction of long-term potentiation in mouse 
hippocampus was shown to be accompanied by an increase of surrounding 
microglial process contacts with dendritic spines, suggesting a potential role 
of normal microglia in activity-induced synaptic plasticity (Pfeiffer et al., 2016). 
Moreover, in vivo microglia depletion in adult mice exhibited impaired 
learning-induced synaptic formation and altered electrophysiological property 
in cortical neurons and also significant learning deficits (rotarod, fear 
conditioning, and novel object recognition) without any signs of inflammation 
(Parkhurst et al., 2013), which suggests a role of ‘resting’ microglia in synaptic 
activity, although another study employing CSF1R inhibitor to deplete 
microglia in adult mice did not observe significant cognitive or behavioral 
changes (elevated plus maze, open field, Barnes maze, rotarod, and fear 
conditioning) after up to 2-month microglial depletion (Elmore et al., 2014). 
Collectively, the surveillance status of microglia seems to be not only a 
scrutinizer of potential threats in the brain but also an important candidate for 
an active sensor and modulator involved in activity-dependent synaptic 
alterations and neuronal circuit remodeling. Further study and more evidence 
are still necessary for validating the exact contribution of microglia to normal 
neuronal synaptic dynamics.    
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Microglia expressing various receptors (e.g. scavenger receptors, Fc 
receptors, toll-like receptors (TLRs), etc.) to receive various signals from their 
domain are the first in the CNS to respond to a variety of stimuli such as 
infections or neuronal damage, so as to resolve the threats and restore the 
CNS homeostasis. The stimuli triggering microglial activation are considered 
to be the presence of an ‘on’ signal (e.g. microbial structure, abnormal protein 
aggregates, abnormal release of intracellular constitutes, and opsonizing 
complements), or loss of an ‘off’ signal (e.g. fractalkine and CD200 signals 
from neurons) (Hanisch and Kettenmann, 2007; Kettenmann et al., 2011). 
Once activation is stimulated, microglia undergo a range of changes within 
seconds to hours, including morphological changes, chemotactic 
reorientation, cytokine release, and other non-transcriptional and 
transcriptional adjustments to support disease defense and tissue repair. 
Notably, microglia are able to acquire distinct activation phenotypes 
depending on different stimulating cues or different stages of disease dynamic 
progression. An M1 or M2 terminology has been widely used to describe 
microglial activation in various studies. This definition first came from in vitro 
macrophages stimulated by TH1 or TH2 cells cytokines, which express distinct 
arrays of cytokines (Boche et al., 2013). The M1 classical activation is defined 
as LPS and/or IFNγ induced macrophage phenotype expressing high levels of 
pro-inflammatory cytokines, which is mainly involved in host defense. The M2 
alternative activation is defined as IL4 and/or IL13 induced macrophage state 
with high expression levels of anti-inflammatory and tissue repairing markers. 
Both types of activation in microglia have also been extensively studied in 
vitro. But this terminology is recently considered to be over-simplified 
(Ransohoff, 2016). The major issue is that, different from microglia polarized 
to M1/M2 states with purified stimuli from various in vitro studies, microglia in 
vivo never receive only one single stimulus to govern their activation states. 
They are modulated by mixed cues including various regulatory/stimulating 
signals from nearby brain cells, emerged pathogens and various cytokines, 
leading to a mixed, dynamic and context-dependent microglial phenotype in 
vivo. Indeed, transcriptomic profile analysis of isolated microglia from either 
healthy or diseased brains did not show the typical M1 or M2 states that were 
revealed by in vitro studies (Holtman et al., 2015; Kim et al., 2016; Morganti et 
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al., 2016); instead ex vivo isolated microglia tended to show a mixed 
phenotype with co-expression of both M1 and M2 marker genes. It is 
becoming obviously inappropriate to simply apply the in vitro M1/M2 category 
to in vivo microglial phenotype. However, the signaling pathways underling 
the activation of M1 or M2 states may still be part of the intrinsic network 
regulating microglia. Various pathways including those involved in M1/M2 
activation might work coherently to regulate microglial phenotypes. Also, the 
balance between M1 and M2 states may still play an important role in 
microglial dealing with environmental stimuli and interacting with neurons. 
Therefore, fine regulation of microglial functions in response to different CNS 
micro-environmental requests seems of extreme importance, and failure to do 
so maybe a critical part of neurological diseases including AD. Practically, 
M1/M2 polarization strategy still provides useful information about how 
microglia behavior under different conditions, especially for dissecting the 
potentially affected pathways when we start to study a certain molecule of 
interest in regulating microglial activation.  
 
 
Microglia and AD 
 
Accumulation and activation of microglia associated with amyloid plaques is 
one of the major AD pathological characteristics, as described in both post-
mortem AD brains and in animal models (Prokop et al., 2013). Development 
of in vivo imaging techniques using the TSPO (18kDa translocator protein) 
radiotracers and PET also provide evidence for microglial activation in AD 
brains (Owen and Matthews, 2011). A recent study employing both prodromal 
and severe AD patients has shown that microglial activation, as measured by 
18F-DPA-714 (a new generation of TSPO radiotracer), positively correlates 
with PiB (a marker for fibrillar amyloid deposition) and occurs at prodromal 
and even possibly preclinical stages of AD (Hamelin et al.). In recent years, 
immune/microglia-related gene variants as AD risk factors revealed by GWAS 
analysis, such as TREM2, CD33, ABI3, and PLCG2 (Griciuc et al., 2013; 
Guerreiro et al., 2013b; Hollingworth et al., 2011; Jonsson et al., 2013; Malik 
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et al., 2013; Naj et al., 2011; Sims et al., 2017) particularly emphasized an 
important role of microglia in AD pathogenesis. However, the question as to 
how microglial activation contributes to AD development is still not completely 
resolved.  
 
Scientists have investigated the potential microglial reactions in response to 
Aβ exposure. It was reported that both soluble and fibrillar Aβ caused 
apparent microglial chemotactic migration and localization in vitro (Cho et al., 
2013), and microglia in culture could be activated by soluble Aβ via the 
scavenger receptor A activity even at very low nanomolar concentrations that 
are below the levels showing obvious direct neurotoxicity (Maezawa et al., 
2011). Furthermore, an in vitro study revealed an assembled complex 
composed of CD36, α5β1-integrin and CD47 as a receptor on microglia 
membrane that binds fibrillar Aβ, mediating microglial activation and pro-
inflammatory mediator secretion (Bamberger et al., 2003). Another study 
showed that CD14, TLR2 and TLR4 were also required for Aβ fibril-induced 
microglial activation and phagocytosis (Reed-Geaghan et al., 2009). 
Conclusively, accumulated evidence from in vitro studies suggests that 
microglia can be effectively activated by various Aβ species. However, what 
should be paid attention to is that microglia in vivo are finely regulated by the 
CNS environment, especially neuronal signals such as CD200 and CX3CL1, 
and retain a unique phenotype with low levels of typical macrophage markers, 
which is easily lost in culturing conditions (Butovsky et al., 2014). Thus in vitro 
microglial responses to Aβ application might be actually oversimplified and 
amplified. It is of critical importance to investigate the exact microglial 
reactions to Aβ pathology either in vivo or in a mixed culture system better 
mimicking the CNS environment.  
 
Transgenic mouse models overexpressing familial AD mutations have 
provided a useful tool for people to investigate microglial changes in response 
to Aβ pathology. Generally, AD microglial activation has already been widely 
replicated in transgenic animal models with Aβ pathology, with an apparent 
expanded microglial population and accumulated microglia surrounding Aβ 
plaques exhibiting enlarged morphology and intensive phagocytic markers 
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(Birch et al., 2014; Liebmann et al., 2016). The accumulation of microglia 
covering plaques has recently seemed of particular neuronal protective 
aspects. For example, it was reported that microglia clustering around 
plaques promoted the plaques to become denser and compact, which 
restricted formation of protofibrillar Aβ ‘hot-spots’ and consequently reduced 
neuritic dystrophy (Condello et al., 2015). Furthermore, studies with TREM2 
deficient mice showing less microglial clustering around plaques supported 
the effects of microglia on compacting plaques and restricting adjacent 
neuritic damage (Wang et al., 2016; Yuan et al., 2016). It thus emphasized 
that the microglial reaction to Aβ does provide protective functions via actively 
affecting Aβ dynamics, rather than just being a secondary event of little 
contribution to the AD progression.  
 
In recent years, transcriptional network analysis of mouse models has 
revealed microglial gene expression signatures associated with 
neurodegenerative diseases, and particularly AD.  In a paper our lab 
previously published, we investigated the gene expression changes in an 
array of mouse models exhibiting different stages of AD-related pathology, 
investing amyloid and tau mouse models separately, and identified a large 
group of microglial genes showing highly connected increased expression 
associating tightly with the Aβ deposition process, which suggested complex 
transcriptional changes in microglia in response to Aβ pathology (Matarin et 
al., 2015). Notably, several hub genes including Trem2 exhibiting particularly 
high connectivity with other genes were highlighted in network analysis, 
perhaps suggesting their coordinating roles in expression of Aβ-induced 
microglial phenotypes. However, because the analyzed brain tissue was 
tested without isolation of specific cell types, the observed changes might be 
partially due to the expansion of the microglial population and also some 
genes’ signals might be too diluted in the mixture of all brain cell types. 
Furthermore, Holtman and colleagues purified microglial population from 
various mouse models for ageing or neurodegenerative diseases and 
identified the gene expression profile related to aged or disease-associated 
microglia (Holtman et al., 2015), which indicated a high overlap in the up-
regulated gene modules. Further GO and KEGG-pathway analysis showed 
	   20	  
that the up-regulated microglial genes in AD mice mainly represented 
involvement in pathways of e.g. immune response, phagocytosis and antigen-
presenting processes, and on the other hand, this phenotype accompanied 
down-regulated steady state microglial genes largely overlapping with 
microglial signature genes found in another study (Butovsky et al., 2014). In a 
very recent paper (Keren-Shaul et al., 2017), a ‘disease-associated microglia’ 
subgroup was found to associate with Aβ plaques in the 5XFAD mouse 
model, and the major signature markers were of a substantial overlap with the 
hub genes obtained from previous published network analyses. Especially, 
they found the expression of this phenotype was partially dependent on 
expression of one of the hub genes, Trem2. Together with the fact that 
GWAS-identified loss-of-function variants of TREM2 increased AD risks, it 
therefore seems that it might play causal regulatory roles in guiding a complex 
microglial phenotype induction in response to Aβ changes; such phenotype 
induction could be protective against further development of pathology, and 
failure to do so (e.g. due to loss-of-function mutations or abnormal 
downregulation of these genes) might result in insufficient or faulty activation 
of microglia leading to less efficient resolution of threats and perhaps 
detrimental effects.  
 
However, the activated microglia in response to Aβ pathology may also 
suggest a loss of normal surveillance status of microglia and probably an 
acquirement of detrimental functions. Stevens’ group found in AD models that 
there was an oligomeric-Aβ-induced reactivation of developmental synaptic 
pruning pathway by microglia, which underlined the synaptic loss and 
plasticity impairment caused by Aβ oligomers (Hong et al., 2016) and was 
mediated by C1q that was found to be one of the ‘hub’ genes in co-expressed 
networks in AD mouse models (Matarin et al., 2015). Considering the normal 
strict microglial phenotype switch from developmental stage to adulthood 
(Matcovitch-Natan et al., 2016), it might be possible that the microglial 
activation phenotype, which is supposed to resolve the Aβ elevation, to some 
extent re-shifts the microglial phenotype away from the mature surveillance 
status and re-gains some of the functions contributing to developmental brain 
modeling but which is then detrimental to the adult brain. The potential 
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neurotoxic roles of microglia in AD were also strongly suggested in a study 
employing microglial depletion via a recently developed CSF1R inhibiting 
strategy (Elmore et al., 2014), showing that elimination of microglia in 5XFAD 
mice resulted in rescued synaptic and neuronal loss without obviously 
affecting Aβ metabolism (Spangenberg et al., 2016). Therefore, detrimental 
functions of activated microglia in response to Aβ dys-homeostasis may also 
exhibit an important role in the Aβ-to-neurodegeneration pathway.  
 
Despite the intensive study of microglia relating to the Aβ pathway, whether 
microglia contribute to tau pathology development still needs more 
investigation. Recently, research has suggested a role of microglia in tau 
propagation. The distribution and spreading of tau aggregates shows a strong 
correlation with AD dementia severity and allows staging of the disease 
(Braak and Braak, 1991; Braak et al., 2011). It was reported that the non-
trans-synaptic propagation of tau depended on microglial uptake of tau 
followed by secretion of tau-containing exosomes (Asai et al., 2015). 
Furthermore, a study provided direct evidence showing clear internalization of 
various tau species by microglia in the brain of mice and AD patients (Bolos et 
al., 2016). It could thus be hypothesized that microglia take up both soluble 
and insoluble tau species from either neuronal release or damaged neurites, 
which on one hand represents debris clearance and tau degradation but on 
the other hand promotes tau propagation; the key point here could be in AD 
whether Aβ- (or other AD-related events)-induced microglia priming would 
affect tau processing of microglia, which could drive microglia towards the 
direction of the detrimental pro-tau-propagation role. Similar to what is 
suggested in Aβ studies, it seems that fine regulation of microglial phenotype 
might be one of the critical factors contributing to the pathology progression. 
GWAS-revealed AD risk factors have provided a few exciting potential 
candidates to such a regulating role in microglia, of which TREM2 is the most 
interesting candidate with which to start.  
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TREM2 
 
TREM2 (triggering receptor expressed on myeloid cells 2) is a 
transmembrane protein containing a single immunoglobulin-superfamily (Ig-
SF) domain. It is part of the TREM gene cluster on human chromosome 
6p21.1, and the mouse orthologue is encoded on mouse chromosome 17d 
(Allcock et al., 2003; Bouchon et al., 2000; Bouchon et al., 2001; Daws et al., 
2001). The TREM gene cluster encodes a group of innate immune receptors 
(such as TREM1, TREM2, NKp44, and various TREM-like transcripts) sharing 
a high degree of similarity, albeit mainly limited to the immunoglobulin-like 
domain that serves as the ligand-binding region.   
 
TREM2 expression is first observed in macrophages and dendritic cells, but 
not granulocytes or monocyte cells (Bouchon et al., 2000; Bouchon et al., 
2001; Daws et al., 2001). It is widely found in various cell types derived from 
the myeloid lineage, such as bone osteoclasts (Humphrey et al., 2006; 
Paloneva et al., 2003), lung (Wu et al., 2015) and peritoneal (Turnbull et al., 
2006) macrophages. In the brain, TREM2 is predominantly expressed by 
microglia (Paloneva et al., 2002; Schmid et al., 2002; Takahashi et al., 2005). 
In 2015, however, Jay et al. questioned the TREM2 expression by microglia in 
the brain, by reporting that TREM2-expressing cells in the 5XFAD mouse 
brain were all expressing high levels of CD45 cells, suggesting a peripheral 
monocyte origin (Jay et al., 2015; Savage et al., 2015). But the expression 
level of CD45 may not be an ideal criterion to classify parenchyma microglia 
versus infiltrating monocytes, because the microglial transcriptional signature 
could be changed upon stimulation. Later on, another study confirmed that 
TREM2-positive cells in the AD mouse brain were actually resident microglia 
rather than infiltrating monocytes using parabiosis experiments (Wang et al., 
2016).  
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TREM2 structure and signaling pathway  
 
The structure of TREM2 is composed of an extracellular region with a single 
V-type immunoglobulin-like domain, a transmembrane domain with a 
positively charged residue, and a short cytoplasmic domain (Bouchon et al., 
2000). The immunoglobulin-like fold in TREM2 protein depends on an intra-
chain disulfide bridge formed by two cysteine residues. As the cytoplasmic 
region is short and does not bear docking motifs for signaling mediators, 
TREM2 has to couple with the adapter protein DAP12 (DNAX-activating 
protein of 12 kDa) to transduce the intracellular signals (Bouchon et al., 2000; 
Bouchon et al., 2001). Additionally, cell surface TREM2 undergoes 
ectodomain shedding by ADAM10 resulting in a soluble TREM2 release, and 
then intramembrane proteolysis by γ-secretase to remove the C-terminal 
fragment (Kleinberger et al., 2014; Wunderlich et al., 2013).  
 
DAP12, belonging to the type 1 transmembrane adapter protein family, is 
expressed as a homodimer at the cell surface and associated with its various 
partner receptors, including KIR receptors, NKp44, TREM1, TREM2, TREM3, 
etc., through an electrostatic association within the transmembrane domain. 
The downstream signaling transduction depends on the ITAM 
(immunoreceptor tyrosine-based activation motifs) present in the DAP12 
cytoplasmic tail.  
 
Upon TREM2 ligation, the tyrosine residues of the ITAM are phosphorylated 
by the Src family kinases, and then recruit and activate the tyrosine kinase 
Syk and/or ZAP70, which in turn initiates a cascade of downstream 
phosphorylation of other proteins (Paradowska-Gorycka and Jurkowska, 
2013). One of the major involved downstream pathways is the PI3K/Akt 
pathway, that is Syk-activated PI3K catalyzes phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), 
recruiting phospholipase C-γ (PLCγ), TEC-family kinases and Vav, which then 
results in recruitment and activation of Akt. Another target of Syk/ZAP70 is the 
LAT/LAB adapter that recruits various signaling mediators upon 
phosphorylation, which consequently converts PIP3 to inositol triphosphate 
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(IP3) and DAG and activates intracellular calcium mobilization, PKCθ and the 
RAS-ERK pathway. Integrated signals then contribute to cellular 
transcriptional regulations.  
 
 
TREM2 ligands 
 
The exact ligand of TREM2 has not been clearly understood. Studies have 
suggested that TREM2 exhibits a pattern recognition feature. It binds to a 
broad range of exogenous (Gram-positive and Gram-negative bacteria) and 
endogenous (astrocytoma cells, various membrane phospholipids, non-
phosphate lipids, and nuclear components) materials, which might be partially 
dependent on recognition of anionic residues (Cannon et al., 2012; Daws et 
al., 2003; Kawabori et al., 2015; Wang et al., 2015). Recently, ApoE 
especially lipidated ApoE has been found as a high-affinity TREM2 ligand in in 
vitro studies (Atagi et al., 2015; Bailey et al., 2015; Yeh et al., 2016), which 
brings a lot of interest because both TREM2 and APOE variants are 
associated with increased AD risk. In addition, other apolipolipids, such as 
ApoA1, ApoB and CLU, and HDL and LDL are also found as potential TREM2 
ligands (Atagi et al., 2015; Song et al., 2017; Yeh et al., 2016).  
 
Rare genetic variants of TREM2 and CNS diseases 
  
The importance of TREM2 function is strongly suggested due to the genetic 
findings of the association between variants of TREM2 or its adapter DAP12 
and human diseases. Homozygous loss-of-function mutations of 
TREM2/DAP12 were first identified as the cause of polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL; also known as Nasu-Hakola disease, NHD) (Dardiotis et al., 2017; 
Kondo et al., 2002; Paloneva et al., 2000; Paloneva et al., 2002), which 
described a rare autosomal recessive disease characterized by multiple bone 
cysts and presenile frontal lobe dementia. As TREM2 is predominantly 
expressed by osteoclasts and microglia in the bone and the brain 
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respectively, these studies have pointed to a critical role of TREM2 in 
regulating the function of these tissue myeloid cells to maintain tissue 
homeostasis.  
 
In 2013, two independent GWAS studies (Guerreiro et al., 2013b; Jonsson et 
al., 2013) highlighted a rare variant rs75932628-T in TREM2 gene exon 2, 
causing an Arginine-to-Histidine substitution at amino acid position 47 (R47H), 
to be highly significantly associated with increased AD risk, with a comparable 
effect size to the APOEε4 allele (around 3-fold increased AD risk). The 
association between the R47H and both early-onset and late-onset AD was 
then verified in a number of studies employing various case populations, and 
besides, such association was confirmed to be independent of the APOEε4 
risk variant (Benitez et al., 2013; Jin et al., 2014; Pottier et al., 2013; Ruiz et 
al., 2014; Sims et al., 2017). Furthermore, the R47H variant was investigated 
in other neurodegenerative diseases; it was also found to be associated with 
frontotemporal dementia (Rayaprolu et al., 2013), Parkinson’s disease 
(Rayaprolu et al., 2013), and amyotrophic lateral sclerosis (Cady et al., 2014), 
suggesting a more widespread role for TREM2-related microglial functions in 
maintaining neuronal function/survival throughout the brain.  
 
In addition to the R47H, more TREM2 variants were revealed to be risk 
factors of AD or other CNS diseases. Another TREM2 exon 2 variant, R62H, 
was recently revealed to significantly associate with AD risk (Jin et al., 2014; 
Sims et al., 2017). The H157Y in TREM2 exon 3 was associated to AD in a 
Han Chinese population (Jiang et al., 2016a), albeit the R47H association was 
not replicated in this population due to an extremely low minor allele 
frequency (Yu et al., 2014). Three homozygous variants Q33X, T66M and 
Y38C, and a compound heterozygous variant [Y38C and D86V] were found to 
cause an FTD-like disorder in four Turkish patients respectively (Guerreiro et 
al., 2013a; Guerreiro et al., 2013c). Notably, Guerreiro and colleagues 
reported significantly more common presence of the heterozygous form of 
Q33X, T66M and Y38C variants in AD patients compared with the healthy 
controls (Guerreiro et al., 2013b; Jonsson et al., 2013). A brief summary of the 
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TREM2 protein structure along with the domain-localization of disease-
associated variants was illustrated in Figure 1.2.  
 
In conclusion, all the TREM2 genetic linkage with neurodegenerative diseases 
suggests an important contribution of TREM2 to regulating microglial 
functions with respect to neuronal function/survival in the process of disease 
progression. In the context of AD, exploring the function and mechanism of 
action of TREM2 in microglia would be extremely worthwhile for our 
understanding of AD mechanisms and particularly the role the immune 
system plays in the disease progression, likely opening novel opportunities for 
therapeutic development.  
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Figure 1.1. Protein structure of human TREM2 with major disease-
associated rare variants highlighted. The panel shows the structure of 
human TREM2 (UP_061838.1, based on NM_018965; sequence 
information obtained from http://www.uniprot.org). The major rare coding 
variants associated with AD and other neurodegenerative diseases are 
indicated. Most variants including the R47H are located in the 
immunoglobulin-like fold of the extracellular domain, except that the H157Y 
that is within the region between the Ig-like loop and the transmembrane 
domain. Particularly, very recent studies suggested that the TREM2 
shedding site was at the H157-S158 bond (indicated with a purple arrow) 
and an effect of H157Y ion TREM2 cleavage (Schlepckow et al., 2017; 
Thornton et al., 2017).  	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TREM2 and microglial function 
 
TREM2 has been suggested to play an important role in phagocytosis and 
inflammation regulations in myeloid cells. TREM2’s impact on microglial 
functions was first investigated by Takahashi et al., who manipulated Trem2 
expression in primary microglia in vitro by transduction of flag-tagged TREM2 
or Trem2 knockdown using lentiviral strategy and suggested TREM2 signaling 
supported microglial chemotaxis and phagocytosis, and inhibited inflammation 
induced by application of apoptotic neurones (Takahashi et al., 2005). TREM2 
was also found to inhibit LPS-induced pro-inflammatory markers upregulated 
in primary alveolar macrophages in vitro (Gao et al., 2013) and the BV2 
microglial cell line (Zhong et al., 2015). With respect to AD, evidence has 
accumulated to support the involvement of TREM2 in microglia/macrophage 
phagocytosis of Aβ. For example, research employing primary microglia with 
either Trem2 knockdown or over-expression via lentiviral strategies showed 
TREM2 facilitated Aβ1-42 uptake accompanied by down-regulation of the 
microglial pro-inflammatory cytokine response (Jiang et al., 2014). Trem2 
RNAi amplified the pro-inflammatory gene expression upregulation in the BV2 
microglial cell line (Zhong et al., 2015). Primary microglial from Trem2 
knockout mice and transfected HEK293 or BV2 cells with TREM2 loss-of-
function NHD/AD-associated variants all exhibited significant reduction in 
phagocytosis of bacteria, fluorescent beads, and Aβ1–42 aggregates, which 
for the first time highlighted the functional changes in microglia due to the 
disease-associated TREM2 variants (Kleinberger et al., 2014). Moreover, 
TREM2 deficient microglia/macrophages were also found to show decreased 
efficacy of antibody-stimulated Aβ uptake both in vitro and ex vivo, probably 
indicating a reduction in the total phagocytic capacity in TREM2 deficient 
myeloid cells (Xiang et al., 2016). As apolipoproteins have been found as 
TREM2 ligands, it was also shown that microglia/macrophages bearing the 
AD-associated TREM2 R47H variant exhibited lower binding affinity to ApoE, 
CLU, and LDL, which resulted in reduced microglial clearance of ApoE-bound 
apoptotic neurons (Atagi et al., 2015), and CLU/LDL-associated Aβ1–42 
aggregates (Yeh et al., 2016). In contrast, primary microglia isolated from 
adult Trem2 knockout mice and cultured in the presence of transforming 
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growth factor β (TGF-β) exhibited no impairment in phagocytosis of either 
apoptotic cells or Aβ compared to WT mice (Butovsky et al., 2014; Wang et 
al., 2015), suggesting different microenvironment factors might modulate the 
potential involvement of TREM2 in microglial phagocytosis.  Overall, TREM2 
is implicated in regulating microglial/macrophage phagocytic activities and 
restricting pro-inflammatory inductions.   
 
 
Exploring TREM2 in AD mouse models 
 
To further clarify the relevance of TREM2 in AD progression in vivo, recent 
studies have manipulated Trem2 expression in AD mouse models and 
investigated the consequent effects on the AD-related pathology 
development.  
 
Brain Trem2 expression is up-regulated along with Aβ deposition in various 
transgenic AD mouse models (Frank et al., 2008; Guerreiro et al., 2013b; Jay 
et al., 2015; Melchior et al., 2010). We have also previously reported in an 
APP/PS1 mouse model that Trem2 is up-regulated in both the cortex and the 
hippocampus, and in particular, microarray analyses combined with network 
analyses highlights Trem2 as one of the ‘hub genes’ showing high 
connectivity to other genes in terms of the transcriptional changes, particularly 
in response to Aβ pathology (Matarin et al., 2015). It is therefore not 
surprising that theses mouse models could potentially be useful tools to 
investigate the functional role of TREM2, and in general, of microglia, in AD-
related pathology progression, although the transgenic mice may not be the 
ideal models to completely mimic AD in humans given their overexpression. 
 
Before addressing TREM2 deficiency in AD mice, it is important to note that 
Trem2 knockout in wildtype control mice does not bring about obvious 
changes in the major brain histology, inflammatory status, neuronal health or 
behavioral performances (Poliani et al., 2015; Zhu et al., 2015), except an 
impairment in microglia increase and morphology change associated with 
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ageing. This microglial impairment observed only in aged or mice modeling 
dementia might suggest a role of TREM2 in modulating microglial functions in 
response to stress in the brain, rather than modulating microglia in healthy 
brains.  
 
As TREM2 is suggested to be critical for microglial phagocytosis, it could be 
particularly relevant in AD as a mechanism for Aβ clearance. So far studies 
employing Trem2 knockout or overexpression have all examined the impact 
on Aβ deposition in various AD mouse models. Indeed, they consistently 
found that TREM2 deficiency led to decreased microgliosis associated with 
Aβ plaques and attenuated microglial transcriptional changes. However, the 
results regarding the change in Aβ load in the brain showed a lot of 
discrepancies (Jay et al., 2017; Jay et al., 2015; Jiang et al., 2014; Jiang et 
al., 2016b; Ulrich et al., 2014; Wang et al., 2015; Wang et al., 2016), which 
has been summarized in Table 1.2. One of the possible causes seems to be 
the different stages of the Aβ pathology progression analyzed. Studies 
investigating mice at early to middle stages of pathology showed that Trem2 
deficiency reduced or did not obviously affect Aβ burden (Jay et al., 2017; Jay 
et al., 2015; Ulrich et al., 2014; Wang et al., 2016), while at late stages an 
increase in the brain Aβ deposition was observed (Jay et al., 2017; Wang et 
al., 2015). The differential interaction between TREM2 and Aβ pathology at 
different stages was also found in Trem2 overexpression studies by Jiang and 
colleagues, in which they showed in vivo Trem2 overexpression significantly 
enhanced microglial uptake of Aβ and ameliorated Aβ deposition only in the 
APPPS1 model at an early-middle stage, but not in aged mice (Jiang et al., 
2014; Jiang et al., 2016b). Collectively, it appears that apart from TREM2-
dependent microgliosis in response to Aβ pathology, TREM2-related 
microglial Aβ phagocytosis may be just one of the factors affecting Aβ 
deposition in the brain, which could also be affected by other factor like Aβ 
kinetics changes, differential microglial activation phenotypes, and possibly 
the functional reserve/capacity of microglial with ageing/stress. This also 
suggests that any therapies developed against TREM2 or microglia for use in 
AD need to be tailored for use at the correct stage of disease. 
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Interestingly, there are two reports both showing that TREM2 deficiency and 
consequent reduced microglia covering Aβ deposits resulted in a significant 
structural change of the Aβ plaques in the 5XFAD mouse model, which 
exhibited a smaller condensed plaque cores with wider fiber-like outwards 
diffusing structures, resulting in increased dystrophic neurites around Aβ 
plaques (Wang et al., 2016; Yuan et al., 2016). This finding possibly suggests 
a barrier function for microglia in insulating Aβ plaques, which could not only 
slow down the plaque growth but also restrict the interface diffusion of soluble 
Aβ from plaques so to limit the soluble-Aβ-induced neuronal toxicity. 
Therefore, TREM2-dependent microgliosis around Aβ deposits could be a 
critical mechanism of the brain to both remove Aβ and inhibit 
neurodegeneration.  
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Table 1.1 
Table 1.1. Effects of Trem2 deficiency/overexpression on Aβ 
pathology in various transgenic AD models. Adapted from Jay et al. 
(Jay et al., 2017). Arrows indicate either increased or decreased pathology, 
and ‘=’ indicates no significant changes observed. 	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TREM2 influence on microglial survival 
 
Microglial survival requires continuous CSF1/IL34-CSF1R activation in the 
mature brain, and withdrawal of CSF1R signaling drives rapid microglial death 
(Elmore et al., 2014). Actually TREM2 was found to be involved in cell survival 
(monocyte-derived dendritic cells in vitro) soon after TREM2 was initially 
identified (Bouchon et al., 2001). Recently, it has been found TREM2/DAP12 
also plays a role in microglial survival, which appears to work synergically with 
the CSF1R pathway. Otero and colleagues found in 2009 that DAP12 
deficiency reduced viability of bone-marrow-derived macrophages in vitro by 
both inhibiting CSF1R-dependent proliferation and promoting macrophage 
apoptosis; mechanistically, it involves attenuated CSF1-CSF1R-signaling-
induced β-catenin activation (tyrosine phosphorylation and nuclear 
translocation) resulted from DAP12 deficiency (Otero et al., 2009). They 
further showed that aged DAP12-/- mice exhibited decreased microglia 
number and increased signs of microglial degeneration compared to WT 
mice, which also supported the contribution of DAP12 signaling to the survival 
of microglia. As TREM2 is one of the major myeloid cell receptors transducing 
downstream signals via DAP12, it is likely that the role of DAP12 in supporting 
cell viability represents a contribution of TREM2. The important role of TREM2 
in myeloid cell survival was then confirmed in bone-marrow-derived 
macrophages (Wu et al., 2015), osteoclast precursor cells (Otero et al., 2012), 
and lung macrophages (Wu et al., 2015). In the context of microglia, Trem2 
deficiency was found to accelerate reduction of microglial viability in vitro 
induced by CSF1R-signaling-deprivation, and in vivo Trem2 knockout did lead 
to more microglial apoptosis in the 5XFAD mouse model (Wang et al., 2015). 
Recently it was shown in primary culture and mouse models that microglia 
required TREM2 activation to efficiently phosphorylate the Akt/GSK3β 
pathway to finely control the degradation of β-catenin that in turn maintained 
microglial survival and proliferation (Zheng et al., 2017). Collectively, 
TREM2/DAP12 may play an important role in the CSF1R-dependent 
microglial survival by regulating the β-catenin signaling pathway, although 
TREM2 does not seem to replace the function of the CSF1R-signaling in 
maintaining microglial survival as TREM2 normal expression does not prevent 
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microglial depletion due to CSF1R blockade (Elmore et al., 2014; Wang et al., 
2015), suggesting two parallel pathways that cross-talk.  
Since soluble TREM2 (sTREM2) was identified, studies have found sTREM 
might contribute to myeloid cell survival as well, which is discussed in the next 
session.  
 
 
Soluble TREM2 
 
Recently a soluble form of TREM2 has captured attention. Soluble TREM2 
(sTREM2) was first described in research by Piccio and colleagues (Piccio et 
al., 2008), which was encouraged by the presence of soluble TREM1 and an 
alternative TREM2 transcript only bearing the extracellular domain (although 
the expression levels of the alternative TREM2 isoform is much lower than 
full-length TREM2) (Allcock et al., 2003; Schmid et al., 2002). They detected 
sTREM2 in both human cerebrospinal fluid (CSF) and plasma, and showed 
that the CSF sTREM2 levels were higher in patients with multiple sclerosis or 
other inflammatory neurological diseases. The presence of CSF and plasma 
sTREM2 was then confirmed by other studies later.  
 
Moreover, research has shed light on the processing of TREM2 protein, which 
by far seems to be the major origin of sTREM2 production. In vitro studies 
utilizing various cell lines transfected with tagged TREM2 suggested that 
TREM2 underwent maturation and localization to cell surface, and then 
ectodomain shedding by ADAM10 resulting in sTREM2 release, and then 
intramembrane proteolysis by γ-secretase to remove the C-terminal fragment 
(Kleinberger et al., 2014; Wunderlich et al., 2013). Remarkably, transfection of 
FTD- or FTD-like-associated TREM2 variants (T66M and Y38C) was found to 
heavily impair TREM2 maturation and transport to cell membrane and thus 
cleavage of TREM2, which led to largely reduced production of sTREM2; the 
AD-associated TREM2 R47H variant also showed similar but much less 
severe effects (Kleinberger et al., 2014). Therefore, routinely proteolysis of 
TREM2 and release of sTREM2 might suggest a potential paracrine or 
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autocrine function of sTREM2 in regulating microglial activities and perhaps 
other cell types in the brain as well.  
 
Under the context of AD, people then started to investigate the relevance of 
CSF sTREM2 in AD. It has been consistently found that the CSF sTREM2 
level is positively associated with ageing, and in AD patients associated with 
CSF total-tau and phosphorylated-tau in AD patients (Henjum et al., 2016; 
Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016a; 
Suarez-Calvet et al., 2016b). A few studies showed CSF sTREM2 levels but 
not plasma sTREM2 were significantly higher in AD patients than in healthy 
controls (Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 
2016a). Investigation of the temporal sequence of various AD marker changes 
showed that the CSF sTREM2 change in AD followed Aβ deposition and 
alterations in CSF Aβ and total-tau, but was concurrent with 
neurodegenerative changes such as hippocampus volume and cognitive 
performance decline, suggesting the CSF sTREM2 change as an event 
occurring at early symptomatic stages of AD but after the initiation of cellular 
pathology (Suarez-Calvet et al., 2016a). However, controversial results were 
also reported as equivalent (Henjum et al., 2016) or lower CSF sTREM2 
(Kleinberger et al., 2014) in AD cases compared to the control population. The 
inconsistency might be due to differences in the sample size, differences in 
ethnicity of populations, the case selection of different pathological stages, or 
the assays used for measurement. Even in the studies showing a significant 
CSF sTREM2 difference in AD versus controls, there was always large 
overlap between groups, suggesting sTREM2 in CSF might not be an ideal 
biomarker for AD diagnosis. However, it could still be a useful marker for 
assessing microglial status and inflammation in the brain, particularly in a 
subset of patients.  
 
It remains unclear in terms of the exact physiological/pathological functions of 
sTREM2. Wu and colleagues found sTREM2 application promoted the 
survival of bone-marrow-derived macrophages via an anti-apoptotic effect, 
whether or not full-length TREM2 was constitutively expressed in these cells 
(Wu et al., 2015). A more recent study (Zhong et al., 2017a) also identified a 
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role of sTREM2 on microglial survival in primary cultures, independent of full-
length TREM2/DAP12 expression, with a mechanism through affecting the 
Akt-GSK3β-β-catenin signaling pathway, suggesting that the previously 
reported influence of TREM2 on microglial survival was at least partially due 
to sTREM2. Additionally, they also found that sTREM2 augmented pro-
inflammatory gene expression in microglia both in vitro and in vivo. 
Interestingly, sTREM2 bearing AD-associated R47H or R62H variants 
exhibited reduced anti-apoptotic and pro-inflammatory functions on primary 
microglia compared to WT sTREM2 (Zhong et al., 2017a), which might be one 
of the potential mechanisms underlying the ‘pro-AD’ effects of theses variants. 
Although the results might need more confirmation, it suggests microglia-
released sTREM2 may serve as an effector for microglia themselves and play 
a role in regulating their survival and functions through an independent 
mechanism of the membrane-tethered-TREM2/DAP12 signaling.   
 
 
Summary 
 
Alzheimer’s disease, the most common cause of dementia, threatens the 
whole society with its particular difficulty of early diagnosis and effective 
intervention. Scientific research since its first description has revealed some 
of the key components in AD pathogenesis such as Aβ dys-homeostasis as 
an early initial factor and tau pathology as a correlate to neurodegeneration 
and cognitive decline. However, there are still many details missing in this 
story, e.g. how Aβ becomes dysregulated given that it is normally produced in 
healthy brains, how Aβ pathology mechanistically leads to tau pathology, and 
how the brain homeostatic system reacts to and contributes to the signature 
pathology, etc. GWAS studies uncovering a variety of AD risk gene variants 
have placed a spotlight on the potential role of the innate immune system 
especially the brain resident microglia in the pathogenesis. In particular, 
TREM2, as one of the strongest risk genes expressed exclusively by 
microglial/myeloid cells in the brain, still retains secrecy for its precise 
biological functions but is likely to perform a regulatory role on microglia, 
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which requires intensive studies to reveal how it contributes to AD, and how 
this information could be utilized for drug discovery.  
 
In this thesis, I established a scheme to investigate the importance of 
microglial GWAS hits for AD that is physiologically-relevant, specifically I 
developed a primary microglial culture model with acute Trem2 knockdown, to 
study subsequent transcriptional changes in the microglia and also the 
microglial fate changes in response to pro- or anti- inflammatory stimuli. In 
particular, the effects were analyzed within a narrow time-window shortly after 
Trem2 was knocked down to identify acute responses of microglia to Trem2 
knock-down and fate-switching stimuli, rather than developmental or chronic 
effects of complete Trem2 ablation for weeks or months, which allows time for 
compensatory and homeostatic changes to cloud our results. I hypothesized 
that microglial Trem2 expression might be very dynamic depending on various 
environmental cues in the brain. In the context of AD pathogenesis, 
accumulating stress with ageing or with other AD risk events could bring 
temporal or continuous changes, and direct or indirect to Trem2 expression, 
which might affect microglial fine regulation in response to potential but still bi-
directional AD initiative events. I found that acute knockdown of Trem2 in 
primary microglia impaired anti-inflammatory or repair-related gene 
transcriptional changes, and identified that Trem2 plays a suppressive role in 
preventing microglia becoming pro-inflammatory. I also validated the 
implication of TREM2 in microglial phagocytosis. Together, the results have 
highlighted an important aspect of TREM2 function that is important for 
dementia, and my data and model of study will allow opportunities for drug 
development.   
 
Additionally, I characterized the microglial activation related to AD pathology 
in two lines of transgenic mouse models that mimic amyloid pathology and tau 
pathology respectively. Particularly, I compared these two models in the 
microglial gene expression levels by RT-qPCR and the microglial population 
changes by immunohistochemistry, in order to investigate the microglial 
reactions in response to different isoforms or stages of AD pathology.  I found 
that the microglial activation followed the time course of the amyloid plaque 
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deposition in the amyloid mouse models, while the tau model presented 
microglial activation with a relative delay to the tangle development but with a 
more pro-inflammatory activation phenotype. More interestingly, although 
Trem2 gene expression was higher in both models compared to the wildtype, 
the increase in Trem2 in the tau mice is largely due to microglial proliferation 
as the ratio to Aif1 expression is largely unchanged whereas in the amyloid 
mice the expression of Trem2 in microglia increases as shown by an 
increased Trem2:Aif1 ratio. 
 
Notably, an obvious limitation of current transgenic mouse models is that they 
overexpress the genes of interest from artificial promoters and the transgenes 
insert randomly into the genome in multiple copies, which is apparently not 
true in human. However, these models are still useful for people to dissect the 
Aβ component of the AD pathology and thus to study the brain immune 
changes in response to Aβ dys-regulation and the neuronal changes at the 
molecular and synaptic levels. Very recently, the APP Knock-in mice were 
developed (Saito et al., 2014), in which APP is expressed from its native 
promoter and so expressed at the endogenous levels (e.g. not 
overexpressed) in the specific cells that normally express APP. This type of 
model, combined with manipulation of AD genetic risk factors, would likely 
provide a better animal model to mimic human AD. Unfortunately, for this 
thesis I did not have enough time to use the knock-in models. 
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Chapter 2 
Materials and Methods 
 
 
All mouse experiments were performed according UK Home office regulations 
under the Animals (Scientific Procedures) Act 1986 and UCL local ethical 
guidelines, and in agreement with the GlaxoSmithKline statement. 
 
 
Mouse models 
 
Both the APP/PSEN1 and TauD35 mice used in this thesis were generated on 
a C57Bl/6 background by GlaxoSmithKline (UK). The APP/PSEN1 mice are 
either homozygous or heterozygous transgenic for the human APP Swedish 
(K670N/M671L) mutation and PSEN1 M146V mutation under the Thy1 (Thy-1 
T-Cell Antigen) promoter (Howlett et al., 2004; Matarin et al., 2015). The 
TauD35 mice are heterozygous transgenic for human microtubule-associated 
protein tau of P301L mutation under the CaMKIIα (Calcium/Calmodulin-
dependent protein kinase II-alpha) promoter (Matarin et al., 2015; Joel, PhD 
dissertation, 2015).  
 
All adult mice used were male for IHC and RT-qPCR. Mice were weaned at 
21 days and then group-housed in individually ventilated cages under 
standard housing conditions with 12-hour light/dark cycle, environment 
enrichment, and ad libitum access to food and water. Housing materials were 
changed weekly. Age-matched C57Bl/6 mice housed under the same 
conditions were used as wildtype controls. Ear- and tail-samples were always 
collected for genotyping with standard PCR. For the TauD35 mice, an 
additional transgene copy number test was performed with TaqMan® qPCR 
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using uniquely designed TaqMan® primers/probes for the CaMKIIα promoter 
sequence by Stuart Martin (Head of the Molecular Biology Unit at UCL). 
 
Primary microglial culture 
 
Primary microglial cultures were generated from cerebral cortices and 
hippocampi of 1-3-day-old wildtype C57Bl/6 mice following an adapted 
protocol of Schildge et al. and Saura et al. (Saura et al., 2003; Schildge et al., 
2013). For each independent preparation of primary microglial culture, brains 
of 4-6 pups from one litter of neonatal mice were dissected and pooled to 
make the cell suspension. On average, around 3,000,000 cortical and 
hippocampal cells per pup were obtained. Specifically, after decapitation, the 
brain was quickly collected and transferred to ice-cold HBSS. The cortices 
and hippocampi from each brain were then dissected, with all other brain 
regions, meninges, and blood vessels removed. Following mechanical and 
chemical (HBSS with 0.25% Trypsin) dissociation, cells were centrifuged, 
collected and seeded (at a density of 120,000 cells/cm2) in poly-d-lysine 
coated flasks with a mixed glial culture medium (high glucose DMEM with 
10% heat-inactivated Fetal Bovine Serum, 100 U/ml Penicillin and 100 µg/ml 
Streptomycin). Cells were cultured at 37°C in humidified 5% CO2 / 95% O2 air 
and the medium was changed every 3 days. After around 19-23 days when 
the mixed glial cells achieved confluency, a mild trypsinization method 
(incubation with DMEM with 0.05% Trypsin and 0.2 mM EDTA for 30-45 
minutes) was applied to purify the primary microglia by removing the 
astrocytic cell layer. Isolated primary microglial cells were collected and 
seeded in poly-d-lysine coated 6-well plates or 24-well plates at a density of 
40,000-100,000 cells/cm2 depending on the following different experiments. 
Pure primary microglia were cultured under the same conditions as the mixed 
glial culture, and experiments were performed around 24 hours after isolation.  
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BV2 cell culture 
 
BV2 cells, a murine microglial cell line, were kindly provided by Dr. Jennifer 
Pocock. Cells were cultured in medium containing DMEM with 10% heat-
inactivated Fetal Bovine Serum, 2mM L-glutamine, 100U/ml Penicillin, 
100µg/ml Streptomycin, and 1% Mycoplasma removal agent (AbD Serotec), 
and passaged every 2-4 days (avoiding confluency of more than 90%). Prior 
to experiments, BV2 cells were collected with Accutase (Sigma, A6964), and 
seeded on 6-well plates at a density of around 10,000 cells/cm2 for testing 
siRNA transfection.  
 
 
Culture treatments 
 
siRNA treatment 
 
Three siRNAs that target mouse Trem2 (Ambion; siRNA No.1 sequences: 
sense 5’-CCCUCUAGAUGACCAAGAUtt-3’, antisense 5’-
AUCUUGGUCAUCUAGAGGGtc-3’; siRNA No.2 sequences: sense 5’-
GCGUUCUCCUGAGCAAGUUtt-3’, antisense 5’-
AACUUGCUCAGGAGAACGCag-3’; siRNA No.3 sequences: sense 5’-
GCACCUCCAGGAAUCAAGAtt-3’, antisense 5’-
UCUUGAUUCCUGGAGGUGCtg-3’) and one non-targeting siRNA used as a 
control (Ambion, Catalog No. 4457287) were suspended in nuclease-free 
water to make 20 µM siRNA solutions and stored at -20°C. BV2 cells were 
used to test these three Trem2 siRNAs and the siRNA No. 2 and No. 3 were 
selected for Trem2 knockdown in primary microglia (See Chapter 3, figure 3.2 
A).  
 
Primary microglia were transfected with either Trem2 siRNA or the non-
targeting negative control siRNA using a transfection reagent Lipofectamine 
RNAiMax (Invitrogen), following the manufacturer’s instructions. For 6-well 
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culture (used for the RNA study), 12.5 pmol siRNA with 3.75 µl Lipofectamine 
was applied per well; for 24-well culture (used for the protein study and 
phagocytosis assay), 2.5 pmol siRNA with 0.75 µl Lipofectamine was applied 
per well. The siRNA/Lipofectamine ratio used per well was 1 pmol siRNA : 0.3 
µl Lipofectamine. Cells were harvested 72±2 hours after transfection.  
 
 
LPS or IL4 treatment 
 
For the microglial activation study, primary microglia transfected with either 
Trem2 siRNA or the negative control siRNA were treated with 1 µg/ml LPS 
(Lipopolysaccharides; Sigma, L4391) around 3, 6, or 24 hours before harvest, 
or 20 ng/ml IL4 (Interleukin 4; PeproTech, 214-14) around 24 or 48 hours 
before harvest. 
 
 
Phagocytosis assay 
 
The phagocytosis assay using the pHrodo Green E. coli BioParticles 
Conjugate for Phagocytosis (Invitrogen, P35366) was adapted from the 
Invitrogen instructions and Kleinberger et al. (Kleinberger et al., 2014). In 
brief, purified primary microglia were cultured on 24-well plates at a density of 
around 50,000 cells/cm2 (100,000 cells/well) and transfected with either 
Trem2 siRNA or the negative control siRNA. After 72 hours, microglia were 
treated with 50 µg pHrodo-conjugated E.coli. per well for 1 hour at 37°C. Cells 
pre-incubated with 10 µmol Cytochalasin-D for 30min prior to the 
phagocytosis assay were used as a negative control. Cells were re-
suspended off the plate with PBS after the assay, and then washed and 
collected in an ice-cold FACS buffer (PBS without Ca2+/Mg2+, with 0.5% BSA, 
0.05% Sodium Azide and 2 mM EDTA). Collected microglia were assessed 
(10,000 cells counted per sample) by flow cytometry (FACSCalibur running 
CellQuest Pro; Becton Dickinson, UK) with excitation at 488 nm and emission 
at a range of 500-535 nm. Following identification of single microglial cells 
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with the expected size and granularity by forward (FSC-H) versus side (SSC-
H) scatter of light, microglia with different amounts of phagocytosed 
fluorescent E.coli and thus with different levels of fluorescent intensity were 
plotted and analyzed using Flowing software (developed by Perttu Terho, 
Turku Centre for Biotechnology, Finland; www.flowingsoftware.com).  
 
 
Molecular biology and immunohistochemistry 
 
Mouse brain tissue extraction for gene expression analysis  
 
Mouse brains were rapidly dissected on ice right after decapitation, and 
hippocampi were then collected, snap frozen on dry ice and stored at -80°C. 
Prior to RNA purification, hippocampi were homogenized using a 
homogeniser in QIAzol RNA lysis reagent (Qiagen) and total RNA was 
isolated with miRNAeasy columns (Qiagen) following manufacturer’s 
instructions, RNA was aliquoted and stored at -80°C.  
 
 
Primary microglia lysing for gene expression and protein analysis 
 
For gene expression analysis, primary microglia were washed with ice-cold 
PBS three times and then lysed in ice-cold QIAzol RNA lysis reagent. Lysed 
cells were snap frozen on dry ice and stored at -80°C. Prior to RNA 
purification, the samples were homogenized using a 1ml syringe and a G21 
needle. Total RNA was isolated using a miRNAeasy columns (Qiagen) 
following manufacturer’s instructions, RNA was aliquoted and stored at -80°C. 
 
For cellular protein lysing, primary microglia were washed with ice-cold PBS 
three times and then lysed in 2X Laemmli dye. Lysed cells were boiled at 
95°C in a heating block for 5 minutes before storage at -20°C.  
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For ELISA, conditioned primary microglial media were collected and 
centrifuged to remove cell debris, and then stored at -20°C.  
 
 
RNA purification and cDNA preparation 
 
Total mRNA from the each sample was purified with the miRNeasy Mini Kit 
(Qiagen) following manufacturer’s instructions. The quality and concentration 
of RNA was assessed with a NanoDrop Spectrophotometer (Thermo 
Scientific), with the A260/A280 ratio typically around 2. RNA samples were 
aliquoted and stored at -80°C before use. 
 
The same amount of RNA from each sample was first treated using DNase I 
(Amplification Grade, Invitrogen) plus RNaseOUT (Invitrogen). The reverse 
transcription reaction was then performed using the High Capacity cDNA 
Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems) following 
the manufacturer’s instructions, in parallel with a negative control lacking the 
reverse transcriptase. The cDNA samples were stored at -20°C. 
 
 
Primer design and test 
 
Primers were designed to span at least two exons and tested for homology 
against the entire transcriptome using Primer-BLAST (NCBI) and ordered 
from Eurofins MWG Operon. All primers were tested for specificity by 
performing a standard PCR reaction and resolving the products on a 3% 
agarose gel with ethidium bromide, followed by a quantitative RT-PCR 
reaction to obtain the linearity range for primers, calculate primer efficiency 
and test primer specificity using a “melt-curve” analysis.  
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RT-qPCR 
 
The cDNA samples were tested in triplicates with a reverse-transcriptase (RT) 
lacking control in a 96-well plate using a CFX96 system (BioRad), with each 
20 µl reaction containing the cDNA dilution, 0.25 µM of forward and reverse 
primers, and SYBR Green PCR Master Mix (Bio-Rad). Cycling conditions 
were: 95°C-3 min, 40 cycles of [95°C-10 sec, 58°C-30 sec and 72°C-30 sec], 
and then 72°C-5 min. A melt curve was generated by heating from 60 to 90°C 
with 0.5°C increments and 5 sec dwell time. All RT-qPCR reactions were 
checked for a single peak with the “melt-curve” analysis signifying a single 
PCR product. The raw cycle threshold (CT) values of target genes (mean of 
the triplicates for each sample) were normalized to Rps28 or Aif1 CT values 
for each sample depending on different experiments.  
 
 
ELISA of secreted TNF-alpha by primary microglia 
 
The TNF-alpha levels in the primary microglial supernatants were quantified 
using Quantikine® Mouse TNF-alpha ELISA kit (R&D Systems, MTA000B), 
following the manufacturer's instructions. In general, equal volumes of cell 
supernatants together with provided buffer were loaded in duplicate to the 
ELISA microplate, and incubated for 2 hours at room temperature. Following 
five times of washing, they were then incubated with the Horseradish 
peroxidase conjugated mouse TNF-alpha for another 2 hours at room 
temperature. The microplate was washed again and incubated with a 
Substrate solution prepared with chromogen (tetramethylbenzidine) and 
hydrogen peroxide for 30 minutes, before addition of a Stop solution with 
hydrochloric acid. Then the colour was read at 450 nm using a plate reader 
(BioTek, EL800) and the TNF-alpha concentrations in microglial supernatants 
were calculated from the standard curve. To account for the differences in the 
cell number between different wells of microglia, cell lysates were collected 
parallel with the supernatants from the same wells and then tested for a 
housekeeping protein HSPA9 (heat-shock protein 9) by Western blot, which 
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was used for normalization of TNF-alpha levels. The normalization factors 
were created by setting the density measure for the HSPA9 band of the 
negative control as 1 and calculating the ratios of the density measures for 
other samples versus the negative control.  Then the TNF-alpha ELISA raw 
data were normalized to the normalization factor for each sample.  
 
 
Cytokine proteome profile  
 
The relative differences of 40 different cytokines / chemokines in primary 
microglial supernatants were tested with the Proteome Profiler Mouse 
Cytokine Array Panel A (R&D Systems, ARY006), following the 
manufacturer's instructions. The nitrocellulose membranes with spotted 
capture antibodies were washed in provided buffer and then blocked for 1 
hour at room temperature. Membranes were next incubated with supernatant 
samples (for each treatment condition, 50µl of supernatants from 4 
independent preparations were pooled together) mixed with a cocktail of 
biotinylated detection antibodies overnight at 4°C. Following washing three 
times, membranes were sequentially incubated with Streptavidin-HRP and 
chemiluminescent detection reagents. The chemiluminescence signal density 
was quantified by use of ImageLab software (v5.2, BioRad). To account for 
the differences in the cell number between different wells of microglia, cell 
lysates were collected parallel with the supernatants from the same wells and 
then tested for a housekeeping protein HSPA9 by Western blot, which was 
used for data normalization.  
 
 
Western blotting of HSPA9 in primary microglia  
 
Cellular protein samples from primary microglia were loaded onto 15% 
polyacrylamide gels and resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). A molecular weight ladder (BioRad) was 
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used for band identification. Then proteins were transferred to a 0.45µm 
nitrocellulose membrane (BioRad) by wet electro-transfer overnight.   
 
Membranes were washed in Tris-buffered saline (TBS; 30 mM NaCl and 30 
mM Tris [pH 7.4]) for 10 minutes, and then blocked in TBS with 0.1% Tween-
20 (TBST) and 5% non-fat milk for 1 hour at room temperature.  Membranes 
were then probed with a monoclonal HSPA9 antibody (BioLegend, MMS-
5164, raised from mouse) that was 1/1000 diluted in blocking buffer overnight 
at 4°C. Following three washes with TBST, membranes were then incubated 
with a Horseradish peroxidase conjugated secondary antibody specific to 
mouse (Jackson ImmunoResearch) that was 1/10,000 diluted in blocking 
buffer for 1 hour at room temperature. Membranes were finally washed 3 
more times, and the Horseradish peroxidase signals were then revealed with 
enhanced chemiluminescence detection (ECL, BioRad). Image acquisition 
and densitometric analysis was performed using ImageLab (v5.2, BioRad).  
 
 
Mouse brain section preparation for immunohistochemistry 
 
Mice were transcardially perfused with PBS, followed by 4% 
paraformaldehyde (PFA), under deep anaesthesia with Euthatal. Intact brains 
were removed, post-fixed in 4% PFA for 24 hours. Brains were then 
transferred into 30% sucrose for cryoprotection and sectioned (transverse to 
the hippocampus) to 30 µm sections using a frozen microtome (Leica). Serial 
sections were collected ~720 µm apart, and stored in PBS with 0.02% Sodium 
Azide. For each batch of immune-staining, a minimum of 3 sections were 
used for each mouse.  
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Immunohistochemistry 
 
Free-floating sections were permeabilized with 0.3% Triton-X 100 in PBS and 
blocked with blocking solution (8% horse serum in PBS with 0.3% Triton-X 
100) for 1 hour at room temperature. Primary antibodies (listed in Table 2.1) 
were diluted in blocking solution and sections were incubated with the diluted 
primary antibody overnight at 4°C. Sections were then washed with PBS-
Triton-X100 three times and incubated for 2 hours at room temperature in 
appropriate secondary antibody dilutions in blocking solution. After three 
washes with PBS and staining with DAPI (1:10,000), sections were mounted 
on SuperFrost Plus slides (Fisher) with Fluoromount G (Scientific Biotech) 
and stored at 4°C until imaging.  
 
 
Immunocytochemistry 
 
Primary microglia plated on poly-d-lysine coated coverslips were fixed with 
2% PFA for 15 minutes at room temperature, followed by five washes with 
PBS. Coverslips were then stored in PBS with 0.02% Sodium Azide at 4°C. 
Prior to immune-staining, coverslips were washed in PBS for 10 minutes and 
blocked for 1 hour at room temperature with 8% horse serum diluted in PBS 
with 0.125% Triton-X 100. Coverslips were then incubated overnight at 4°C 
with IBA1 antibody (Wako, 019-19741) 1:1000 diluted in the blocking solution. 
After primary antibody incubation, coverslips were washed three times with 
PBS and then incubated for 2 hours at room temperature in the secondary 
antibody dilution in blocking solution. After three washes with PBS and 
staining with DAPI (1:10,000), coverslips were mounted on SuperFrost Plus 
slides (Fisher) with Fluoromount G (Scientific Biotech) and stored at 4°C until 
imaging.  
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Imaging and analysis 
 
As APP/PSEN1 mice at late stages showed heavy accumulation of microglia 
around plaques, which made it difficult to analyze the IBA1 and CD68 co-
staining with an epifluorescent microscope, we instead used a two-photon 
confocal microscope (Olympus BX50WI) with a 60X oil immersion objective 
and Olympus FluoView software 300, to image the IBA1 and CD68 staining in 
sections from APP/PSEN1 mice and age matched wildtypes. Images (300µm 
x 300µm area) were taken in the DG (the inner blade) and CA1 regions of 
hippocampus by a z-stack scanning (around 16µm thick, 2µm steps). Images 
were analyzed with ImageJ software for microglial counting. Three sections 
were used to calculate the mean for each animal.  
 
 
Table&2.1&
Primary 
Antibody Target Supplier Dilution 
IBA1 C"terminus+of+IBA1+(ionised+
calcium"binding+adaptor+1)+ ++
Wako,+
019"19741+ 1:+500+
CD68 Mouse+macrosialin+ BioRad,+MCA1957+ 1:+500+
MHC-II 
Mouse+major+
histocompaHbility+complex+
class+II,+I"A+and+I"E+subregion"
encoded+glycoproteins+
eBioscience,+
14"5321++ 1:+200+
Table 2.1. Primary antibodies used in the present study. Details of their 
corresponding antigens, as well as suppliers and dilution used are 
indicated. 
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For the APP/PSEN1 and TauD35 MHC-II staining and the TauD35 
IBA1/CD68 co-staining, sections were imaged using an EVOS® FL Auto Cell 
Imaging System (Life technologies). Images of the whole hippocampal region 
were taken under a 20X objective by area-defined serial scanning. Images 
were then analyzed with Adobe PhotoShop CS6 software. For the IBA1 and 
CD68 staining in TauD35 mice, an area of 360µm x 360µm was defined in the 
DG (the inner blade) and CA1 regions of hippocampus for cell counting. For 
the MHC-II staining in both APP/PSEN1 and TauD35 mice, quantification of 
all positive cells in the whole hippocampal region was performed. For 
comparison of microglia in the CA1 layers amongst APP/PSEN1 and TauD35 
mice, an area of 240µm x 120µm was defined for quantification in each layer 
of the hippocampal CA1 region. Three sections were used to calculate the 
mean for each animal.  
 
Coverslips were imaged using an EVOS® FL Auto Cell Imaging System (Life 
technologies) under a 20X objective. Two coverslips per sample were used 
and three fields of view (480µm x 360µm) per coverslip were taken. IBA1+ 
cells and DAPI were counted with Adobe PhotoShop CS6 software and the 
microglial purity was calculated as a percentage of the IBA1 cell counts 
versus the DAPI counts in the same field of view.  
 
 
Statistics 
 
Data are shown as Mean ± SEM. The sample size (n) represents the number 
of independent experiments for Chapter 3 and the number of mice for Chapter 
4 and 5. All statistics were performed using Microsoft Excel and Prism v6.2 
(Graphpad). For the primary microglial gene expression changes with Trem2 
knockdown versus the non-targeting siRNA control, single gene expression 
level was normalized as a percentage of the control group within each 
independent microglial culture preparation, and then a one-sample t-test was 
conducted for statistical analysis. For the LPS or IL4 treatment experiments, 
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to assess the impacts of Trem2 knockdown and LPS/IL4 treatment on the 
gene expression, each sample was normalized as a percentage of the non-
targeting siRNA, non-LPS/IL4 treated control within each independent 
microglial culture preparation, and then two-way ANOVAs were conducted 
with multiple comparisons when appropriate. For the phagocytosis 
experiment, paired t-test was used to compare the Trem2 knockdown group 
and the non-targeting siRNA control group (samples from the same microglial 
culture preparation were paired). For other experiments, differences between 
two group means were analyzed using Student t-tests, while two-way 
ANOVAs (with multiple comparisons when appropriate) were used to compare 
data with multiple factors, such as age and genotype. Differences were 
considered significant if p<0.05. 
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Chapter 3 
Acute knock-down of Trem2 in primary 
microglia impairs phagocytosis and anti-
inflammatory functions  
 
 
Introduction 
 
TREM2 is predominantly expressed by microglia in the brain and implicated in 
neurodegenerative diseases, particularly in AD, but not exclusively. In this 
thesis, I developed a strategy to investigate the role of microglial genes that 
have been shown to have risk factor variants in GWAS studies expressed in 
microglia using primary cultures and acute knock-down of gene expression 
using RNAi. I then used this strategy to explore the effects of acute Trem2 
expression deficiency on primary microglia at the transcriptional and 
functional levels, especially when polarized towards the pro-inflammatory or 
anti-inflammatory phenotypes.  
 
Evidence from in vitro studies has accumulated to support the role of TREM2 
in inhibiting inflammation and phagocytosis. It was firstly reported in a study 
using primary microglia transduced with flag-tagged TREM2 that cross-linking 
of TREM2 stimulated microglial chemotaxis and phagocytosis of fluorescent 
beads (Takahashi et al., 2005). They also showed that Trem2 knock-down via 
lentiviral strategy increased pro-inflammatory gene expression and decreased 
phagocytosis of labeled apoptotic neuronal membranes in the primary 
microglia stressed with co-culture of apoptosis-induced primary neurones. 
TREM2 was also found to inhibit LPS-induced pro-inflammatory markers up-
regulated in primary alveolar macrophages in vitro (Gao et al., 2013) and the 
BV2 microglial cell line (Zhong et al., 2015). With particular respect to AD, 
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phagocytosis of Aβ was found to be impaired due to reduced mature TREM2 
cell surface expression in studies with primary microglia from Trem2 knockout 
mice and Trem2 mutated microglial cell lines (Kleinberger et al., 2014; Xiang 
et al., 2016). Recently, it was further shown that apolipoproteins acted as 
ligands of TREM2 to facilitate microglial phagocytosis of Aβ and apoptotic 
neurons (Atagi et al., 2015; Yeh et al., 2016). In general, it suggests that 
Trem2 deficiency exacerbates microglial pro-inflammatory activation in 
response to various stimuli, and accompanied by impaired phagocytosis.  
 
In this thesis, I not only further validated the effects of Trem2 deficiency on 
microglial phagocytosis and pro-inflammatory responses, but I also 
particularly studied its effects on microglial polarized to the anti-inflammatory 
phenotype. The current studies have not addressed the anti-inflammatory 
roles of TREM2 well, and I decided to test these functions in the primary 
microglia. Importantly, I employed the primary microglial culture from wild type 
mice and induced acute Trem2 knock-down, after the microglia developed 
normally in vivo allowing us to study more direct effects of TREM2, not diluted 
by compensatory changes that may occur during chronic Trem2 inhibition, as 
in Trem2 knock-out studies. This system also allowed investigation of the 
regulation of microglial Trem2 expression upon different stimulations, and the 
effects of temporal Trem2 decreased expression on a variety of microglial 
fates assessed by gene expression and functional assays. In order to 
understand further mechanisms regulated by TREM2, I also initiated 
experiments to identify novel pathways that are affected by TREM2 in this 
model. 
 
 
Hypotheses and aims 
 
1. It is hypothesized that Trem2 expression is dynamically regulated in 
microglia to adjust for different functional requirements in response to 
different stimuli. Aim: using LPS and IL4, to induce pro- and anti- 
inflammatory activation of microglia, and investigate the Trem2 
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expression change along with the time course of stimulation.   
2. Trem2 deficiency, even acutely induced, could result in microglial gene 
expressional profile and functional changes. Aim: to inhibit Trem2 
acutely using RNAi to investigate the effects of Trem2 deficiency on 
microglial gene expression and phagocytosis.   
3. TREM2 suppresses pro-inflammatory functions of microglia, and 
supports anti-inflammatory roles. Aim: to investigate whether the 
Trem2 deficiency result in impairment or dys-regulated microglial pro- 
and anti- inflammatory responses using LPS and IL4 as stimulators of 
these fates.  
 
 
Results 
 
Establishment of an in vitro model of acute Trem2 knock-down  
 
To specifically elucidate the implications of acute Trem2 deficiency in robustly 
developed microglia, I established an in vitro model where primary microglia 
collected from P1-3 newborn mice (after normal embryonic development) 
were kept in mixed glial cultural conditions to fully develop for ~21 days before 
isolation and acute Trem2 knock-down (figure 3.1 A). The generation of 
primary microglia is described in detail in the ‘Materials and Methods’ chapter.  
 
To induce acute Trem2 knock-down, a siRNA against Trem2 was applied 
accompanied with Lipofectamine RNAiMax ~24 hours after pure microglia 
were isolated from the mixed glial culture (the knock-down group). Cells in 
the same plate treated with a non-targeting siRNA and Lipofectamine were 
used as a control (the control group). Primary microglia were harvested ~72 
hours after siRNA was applied for analysis. To induce classical pro-
inflammatory activation or alternative anti-inflammatory activation, cells were 
treated with LPS or IL4 at certain time points before harvest (figure 3.1 A).  
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The purity of our primary microglial culture was validated (97.22±0.32%) via 
immunocytochemistry by IBA1 and DAPI double-staining (figure 3.1 B). 
Additionally, consistent with Saura and colleagues’ description (Saura et al., 
2003), the majority of the microglia showed a typical elongated morphology 
(bipolar or unipolar), with a small proportion of amoeboid as well.  
 
In order to validate the capacity of the microglial culture to be polarized in the 
direction of either pro- or anti- inflammatory phenotype, LPS or IL4 was 
applied and gene expression of typical pro-inflammatory (Tnf and Il1b) or anti-
inflammatory (Arg1 and Tgfb1) genes was analyzed via RT-qPCR (figure 3.1 
C). Microglia without LPS expressed low transcriptional levels of Tnf and Il1b; 
while with LPS treatment we observed a remarkable increase in the mRNA 
levels of Tnf and Il1b (presented as early as 3 hours after LPS application, 
and consistently >600-fold up-regulation for Tnf and >4000-fold for Il1b at 24 
hours). In contrast, IL4 treatment induced a significant time-dependent up-
regulation of the Arg1 and Tgfb1 expression (figure 3.1 C). Arg1 expression, 
undetectable in our non-stimulated microglia, reached levels well above 
detection threshold at 24 hours and by 48 hours expression levels had further 
doubled. Tgfb1 expression showed around 150% up-regulation at 24 hours 
and 200% at 48 hours. These expected changes in Tnf and Il1b, and Arg1 
and Tgfb1, validate that LPS and IL4 can be used in this system of primary 
microglia to promote a pro-inflammatory and anti-inflammatory fate 
respectively.   
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Figure 3.1. Establishment of our in vitro primary microglial model of acute 
Trem2 knock-down. (A) Schedule of the in vitro Trem2 knock-down model. (B) 
Primary microglia were stained with IBA1 and DAPI. The purity of microglia was 
calculated as the percentage of IBA1 positive cells relative to all nuclei visualized 
by DAPI staining. A higher-magnification image showed the morphology of 
microglia in vitro. (C) Pro- and anti-inflammatory gene expression up-regulation in 
primary microglia with LPS or IL4 treatment respectively. Gene expression in each 
condition was calculated as a percentage versus that in the control cells within the 
same experiment. N = 3-6 independent experiments. Data shown as Mean ± 
SEM.  
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Acute Trem2 knock-down and subsequent transcriptional changes 
 
To determine the efficiency of different Trem2 siRNA sequences, in vitro tests 
using BV-2 cells were first performed. Transfected cells were sampled at 24 
and 48 hours and assessed for Trem2 expression levels by RT-qPCR (Figure 
3.2 A). As expected, BV-2 cells with the non-targeting siRNA showed 
substantial Trem2 mRNA expression at 24 hours, which further increased at 
48 hours as the cells proliferated in culture. I tested three different siRNA 
sequences, and identified one siRNA (Sequence 2) that was highly effective, 
with >80% knock-down of Trem2 transcription compared to the control. I thus 
decided to use this siRNA sequence in the following primary microglia 
experiments. The next effective siRNA against Trem2 was Sequence 3, giving 
50-60% knock-down of Trem2; this second siRNA was used to confirm key 
findings in the primary microglia were dependent on the levels of Trem2 
expression.  
 
Although the microglial purity of the primary culture was as high as ~97%, I 
noticed a substantial loss in the microglial number after Trem2 knock-down, 
which could result in a decrease of the proportion of microglia in the culture. 
As a potential measure of altered microglial proportions in culture, Aif1 mRNA 
levels were also found to be largely decreased in the knock-down cells 
compared to the control, which however this was not observed in BV2 cells 
(figure 3.2 B). Therefore, to normalize the effect of the microglial proportion 
change in the cultures on the microglial mRNA levels, I use Aif1 as the 
housekeeping gene to normalize the gene expression of microglia.  
 
The Trem2 knock-down in the primary microglia performed consistently well 
(figure 3.2 C), and an average of 71.27±1.01% decrease in the Trem2 
expression was obtained. To understand the genetic pathways regulated by 
TREM2, I then investigated the subsequent gene expression changes, if any, 
in the Trem2-knock-down microglia. I searched for genes that we previously 
found to be potentially implicated in AD in the same genetic network as 
TREM2 following a microarray study of AD mouse models (Matarin et al., 
2015), or genes that played an important role in microglial maintenance and 
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homeostasis. As the raw gene expression levels of the primary microglia 
showed a substantial variation among different batches of microglial 
preparations, I analyzed the relative changes compared to the control group 
within each preparation. Among the genes investigated, the C1qa expression 
level was not significantly changed in the knock-down group; however, I found 
that there was a significant down-regulation of the expression of genes Cd68, 
Csf1r, Igf1, Spi1, and Pi3kcg, albeit only by a small percentage, at 72 hours 
after siRNA transfection (figure 3.2 D).  
 
Furthermore, to elucidate whether the gene expressional changes were due 
to Trem2 knock-down or any off-target effects of the transfection, I performed 
an independent trial using an alternative Trem2 siRNA sequence (Sequence 
3). This alternative siRNA produced around 60% knock-down in the primary 
microglia (figure 3.3 A). I tested the expression change of two major genes I 
found significantly affected by Trem2 knock-down using the first siRNA – Igf1 
and Csf1r. As shown in figure 3.3 B, the Igf1 expression was consistently 
significantly down-regulated by both siRNAs in the model, and related to the 
levels of Trem2 expression. While the significant Csf1r down-regulation I saw 
previously was not observed here, I did see the same trend of a decrease 
(figure 3.3 B), the lack of significance is likely due to a small sample size (n=3 
independent cell preparations in combination with the small effect size). 
Overall, the two independent siRNA sequences against Trem2 produced 
similar results suggesting that this RNAi approach to study TREM2 function is 
capturing at least some of the effects of TREM2 with limited non-specific 
effects of using RNAi. In total, acute Trem2 knock-down produced a slight but 
significant change in the gene expression profile of microglia, which might 
result in a shift of microglial functional phenotype.  
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Figure 3.2. Trem2 knock-down (>70%) and its influences on gene 
expression in primary microglia. (A) Trem2 siRNAs were tested in BV2 
cell culture (N=3). The siRNA No. 2 was chosen for the following in vitro 
acute Trem2-knock-down experiments due to its high knock-down levels. 
Key results were also tested with siRNA No. 3. (B) With Trem2 KD there was 
a dramatic decrease in Aif1 mRNA levels in primary microglia, which was not 
observed in the BV2 cell line. In order to account for any microglial cell loss 
after Trem2 KD, the expression level of all other microglial genes was 
normalized to Aif1. (C) Trem2 efficiency was tested with RT-qPCR at 72 hr 
after transfection. Trem2 mRNA levels showed a 71.27±1.01% decrease. (D) 
Significant microglial gene expression changes relative to Control were 
observed at 72 hr after Trem2 siRNA transfection. The mRNA levels of 
individual genes were first normalized to Aif1, and then the relative 
percentage change in KD was calculated versus Control from the same 
batch of cell preparation. N=13 independent cell preparations. Data shown 
as Mean ± SEM. One-sample t-test; * p<0.05, ** p<0.01.  	  
	   59	  
 
 
 
 
Figure'3.3'
A.'
Ge
ne
'e
xp
re
ss
io
n'
le
ve
l''
(%
'c
ha
ng
e'
vs
.'C
tr
l.)
' **'
B.'
Tr
em
2'
re
la
=v
e'
ex
pr
es
si
on
'
(%
'c
ha
ng
e'
re
la
=v
e'
to
'C
tr
l.)
''
0
20
40
60
80
100
120
0
50
100
Alternative Trem2 siRNA 
sequence
Trem2 siRNA used for 
experiments
0
20
40
60
80
100
120
0
20
40
60
80
100
120
**'
Csf1r* Igf1*
Trem2*
Figure 3.3. Effects of an alternative Trem2 siRNA to validate the gene 
expression changes resulting from Trem2 knock-down. (A) An 
alternative siRNA sequence (No. 3 from Figure 3.2A) was transfected into 
the primary microglia, and the previously employed siRNA (No. 2 from Figure 
3.2A) was also used with cells from the same batch of preparation so that a 
comparison could be performed. Both siRNAs produced stable Trem2 KD 
relative to Control when analyzed at 72 hours after transfection. (B) Two 
major genes we found to be affected by acute Trem2 KD in the previous 
Figure 3.2 were analyzed via RT-qPCR in the alternative-siRNA-treated 
microglia. The Igf1 downregulation was replicated in both conditions treated 
with either the alternative siRNA or the first siRNA, while Csf1r was not 
significantly changed by Trem2 KD in this trial although a similar decreased 
trend was observed. N=3 independent experiments. Data shown as Mean ± 
SEM. One-sample t-test; ** p<0.01.  	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Attenuated phagocytosis of microglia with Trem2 knock-down 
 
I then investigated if acute Trem2 knock-down resulted in any functional 
change in the primary microglia, such as phagocytosis. Previous studies have 
already shown impaired phagocytosis in the primary microglia isolated from 
Trem2 knockout mice and cell lines transfected with FTD-like or AD 
associated TREM2 mutations (Kleinberger et al., 2014). Here I investigated if 
acutely induced Trem2 deficiency via RNAi in primary microglia affected the 
phagocytic activity. A phagocytosis assay was performed around 72 hours 
after siRNA transfection, testing the ability of microglia to phagocytose pHrodo 
(pH-sensitive fluorescent dye) conjugated E. coli and quantification of the 
microglia containing the fluorescent bacteria by fluorescence-activated cell 
sorting (FACS). As a negative control, phagocytosis was inhibited with 
Cytochalasin D (a potent inhibitor of actin polymerization) before addition of E. 
coli. We found that microglia with Trem2 knocked down showed a significant 
reduction (~48.1±9.1%) of phagocytosis compared to the non-targeting siRNA 
treated microglia (figure 3.4).  
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Figure 3.4. Impaired phagocytosis in primary microglia with acute 
Trem2 knock-down. Primary microglia were transfected with Trem2 siRNA 
or   non-targeting siRNA for 72 hr, and then a phagocytosis assay was 
performed using pHrodo conjugated E. coli and the number of microglia 
containing fluorescence was quantified by FACS. As a negative control, 
phagocytosis was inhibited with 10 mM cytochalasin D 30 min before 
addition of E. coli. Left and middle: a representative experiment. Left: 
forward (FSC-H) versus side (SSC-H) scatter of light to allow identification 
of single microglial cells of the expected size and granularity (shown within 
the blue gate). Middle: frequency of microglia containing different levels of 
phagocytosed fluorescent bacteria. Right: Microglia with Trem2 knocked 
down showed significant reduction (~48.1±9.1%) of phagocytosis. N=3 
independent experiments. Data shown as Mean ± SEM. Paired t-test 
(paired within each culture preparation); ** p<0.01.  	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LPS stimulation dramatically suppresses Trem2 gene expression in 
primary microglia. 
  
To begin to investigate how Trem2 expression is regulated, microglia were 
stimulated with LPS to induce classical pro-inflammatory responses. I first 
found that, in the control cells, LPS treatment induced dramatic down-
regulation of Trem2 expression (figure 3.5 A), which was consistent with the 
previous findings shown with primary mixed glial cell culture and peritoneal 
macrophage cell cultures (Schmid et al., 2002). The time course analysis 
showed that the Trem2 expression dropped to as low as around 40% of the 
non-stimulated cells from as early as 6 hours after LPS addition, and even 
lower at below 10% by 24 hours. This suggests that pro-inflammatory 
conditions might inhibit microglial Trem2 expression and possibly functions as 
well, which might result in a temporary ‘Trem2 deficiency’ in microglia.  
 
TNF-alpha and IL-1β are two typical pro-inflammatory markers that are 
upregulated in microglia upon LPS stimulation. The expression levels of Tnf 
and Il1b highly increased in our LPS-treated microglia from as early as 3 
hours after LPS application. To investigate whether Trem2 regulates this pro-
inflammatory state in microglia, I knocked down Trem2 expression and did not 
see significant changes in such upregulation of Tnf or Il1b at the 
transcriptional level (figure 3.5 B). This result was not surprising, and 
supported the finding that microglial Trem2 expression was largely inhibited 
upon LPS stimulation. I further investigated if the protein level of TNF-alpha 
released from the microglia in response to LPS was affected by acute Trem2 
knock-down. Different from the transcriptional results, ELISA analysis of the 
microglial-conditioned medium showed that the production of TNF-alpha was 
significantly higher in the LPS treated Trem2-knock-down group than the 
control group with LPS (figure 3.6; p<0.01, Two-way ANOVA followed by 
Sidak’s post hoc test). Collectively these findings show that pro-inflammatory 
stimuli such as LPS can suppress Trem2 expression, and that by inhibiting 
Trem2 expression the microglial cell can take on a stronger pro-inflammatory 
status, in this case producing more secreted TNF-alpha protein when Trem2 
expression is knocked down by RNAi.   
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Figure 3.5. Remarkable Trem2 suppression induced by LPS stimulation 
and no significant effects of Trem2 knock-down on the pro-
inflammatory gene upregulation. (A) Trem2 gene expression showed a 
dramatic time-dependent decrease in the primary microglia with LPS 
stimulation. Gene expression levels were calculated as percentage changes 
relative to Control without LPS treatment from the same batch of culture 
preparation (dotted line at 100% representing levels of Trem2 expression in 
Control without LPS). (B) Tnf and Il1b expression, as examples of pro-
inflammatory genes, were largely up-regulated in primary microglia after 
LPS application. There was no significant difference between Trem2 KD and 
Control.  
N=3 (3hr), 3 (6hr), and 5 (24hr) independent microglial preperations. Data 
shown as Mean ± SEM. Two-way ANOVA followed by Sidak’s post hoc test 
if there was significant interaction; Significant main effects of LPS incubation 
time and Trem2-KD indicated by horizontal and vertical lines respectively, 
post hoc test significance marked above individual groups, * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 	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Figure 3.6. Increased TNF-alpha release from Trem2 deficient primary 
microglia in response to LPS. ELISA analysis of the microglial	  conditioned 
medium showed that the TNF-alpha levels in the medium was significantly 
higher in the LPS-treated Trem2-KD group than in the LPS-treated Control 
group. As there was a potential change in the cell number under conditions 
of LPS or Trem2 siRNA treatment, HSPA9 was employed as a 
housekeeping protein to normalize the TNF-alpha ELISA data. Cells in each 
well were harvested in 150µl Laemmli buffer, and then 20µl cell lysates of 
each well were loaded for HSPA9 Western blot analysis. The density values 
of bands were used to create normalization factors for TNF-alpha analysis. 
N=4 independent microglial preparations. N = 4 independent experiments. 
Data shown as Mean ± SEM. Two-way ANOVA followed by Sidak’s post hoc 
test if there was significant interaction; Significant main effects of LPS 
treatment and Trem2-KD indicated by horizontal and vertical lines 
respectively, post hoc test significance marked above individual groups, * 
p<0.05, ** p<0.01, **** p<0.0001. 	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The expression levels of the microglial genes, which was tested in the 
previous section for Trem2-knock-down effects (figure 3.2), were also 
analyzed in response to the LPS conditions (figure 3.7). Genes such as C1qa, 
Cd68 Csf1r, and Igf1, showed a similar pattern of significant time-dependent 
down-regulation in the microglia with LPS stimulation. Expression of the Spi1 
transcription factor in the microglia with LPS showed at least a 2-fold 
increased level compared to that in the control group, which was observed to 
start as soon as from 3 hr after application, and maintain until at least 24 hr. 
Pik3cg was also up-regulated with LPS, but only observed at the very early 
stages (3 hr) of the LPS treatment. The gene expression changes caused by 
Trem2-knock-down, which I observed previously (figure 3.2 D), were masked 
in the LPS-treated cells, which is not unexpected given that LPS is strongly 
suppressing Trem2 expression. 
 
These data together suggested that microglia polarized to the classical pro-
inflammatory phenotype exhibited largely suppressed Trem2 gene 
expression, which in turn could inhibit TREM2-related functions. Trem2 
deficiency seemed to produce limited effects on the pro-inflammatory 
activation of microglia, although there is some evidence to suggest that 
inhibiting Trem2 expression promoted a stronger pro-inflammatory response, 
particularly the levels of secreted TNF-alpha were significantly increased.  
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Figure 3.7. Changes of microglial gene expression in primary microglia 
with LPS. Microglial C1qa, Cd68, Csf1r, and Igf1 expression showed similar 
time-dependent decreasing patterns in response to LPS treatment, although 
with different kinetics. Spi1 expression showed around 2-fold up-regulation 
in response to LPS, which was observed to start at least from 3 hr after 
application and maintain at that level until 24 hr. Pi3kcg was also up-
regulated with LPS, but only observed at the very early stage (3 hr) of LPS 
treatment. Trem2 KD did not significantly affect the expression changes of 
these genes in response to LPS stimulation.  
N=3 (3hr), 3 (6hr), and 5 (24hr) independent experiments. Gene expression 
levels were normalized to Aif1 levels within samples, and then calculated as 
percentage changes relative to Control without LPS treatment from the 
same batch of culture preparation. Data shown as Mean ± SEM. Two-way 
ANOVA; Significant main effects of LPS incubation time and Trem2-knock-
down indicated as horizontal and vertical lines respectively, no interactions 
between these two factors for all the genes in the figure here; * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 
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Trem2 is involved in microglial anti-inflammatory responses with IL4 
 
Next I studied the effect of acute Trem2 knock-down on the alternative anti-
inflammatory activation of microglia. IL4 was applied to the cells with either 
siRNA against Trem2 or the non-targeting siRNA and cells were analyzed at 
24 hours and 48 hours after IL4 addition. I first found that Trem2 expression 
exhibited a significant time-dependent up-regulation in response to IL4 
treatment (figure 3.8 A). At 24 hours after IL4 application, the Trem2 
expression was still comparable to that of the non-stimulated control group, 
while at 48 hours it rose to 149.5±17.1% of the control. The Trem2 knock-
down group also showed a similar pattern in response to IL4, but as expected 
with significant lower levels than the control group.  
 
I next investigated two anti-inflammatory markers Arg1 and Tgfb1 (figure 3.8 
B). The Arg1 gene expression was undetectable under the non-stimulated 
conditions by RT-qPCR. Upon IL4 treatment, expression was observed, and 
both the control and the knock-down groups showed a significant time-
dependent up-regulation, and in particular, the Trem2-knock-down group 
exhibited significant lower Arg1 up-regulation compared to the control group 
(p<0.01 for the main effect of IL4 treatment time, p<0.05 for that of Trem2 
knock-down, no significant interaction, Two-way ANOVA). Similarly, the Tgfb1 
expression also showed a time-dependent increase with IL4 stimulation, and 
a trend towards a significant effect of Trem2 knock-down on such Tgfb1 up-
regulation (p<0.001 for the main effect of IL4 treatment time, and p=0.059 for 
that of Trem2 knock-down, Two-way ANOVA). In total, acute Trem2 knock-
down attenuated the microglial anti-inflammatory gene up-regulation in 
response to IL4. 
 
Furthermore, the gene expression levels of pro-inflammatory markers Tnf and 
Il1b were analyzed (figure 3.8 C). Both markers were expressed at relatively 
low levels in the non-stimulated control conditions, which were further 
decreased modestly with IL4 treatment. Significant differences between the 
control and the knock-down microglia were only observed in the Il1b levels 
(p<0.01 for the main effect of IL4 treatment time, p<0.05 for that of Trem2 
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knock-down, no significant interaction, Two-way ANOVA). The tendency for 
elevated Il1b with Trem2 knock-down suggests that Trem2 may be required to 
suppress pro-inflammatory function in response to anti-inflammatory cues.     
 
Next to understand which genetic pathways are regulated by TREM2 in anti-
inflammatory conditions I investigated the expression of the genes tested in 
previous sessions under the IL4 conditions (figure 3.8). The C1qa gene 
expression, which was not affected by Trem2 knock-down in the non-
stimulated state (figure 3.2 D), was upregulated in response to IL4 stimulation 
(~150-200% of the level in non-stimulated conditions), although there was no 
significant time-dependent change. Two-way ANOVA analysis showed a 
lower trend in the knock-down group than the control group under the IL4 
conditions (p=0.055), and particularly a significant interaction between IL4 
treatment and Trem2 knock-down (p=0.034). Sidak’s post hoc analysis 
displayed a significantly lower C1qa expression in the knock-down group than 
the control at 48 hours after IL4 application (p=0.029). The Csf1r gene 
expression under the IL4 condition, which upregulated by a similar percentage 
to C1qa, was found to be significantly lower in the knock-down group than in 
the control group (p=0.029, Two-way ANOVA). In contrast, the genes Cd68 
and Igf1, previously found to be downregulated by Trem2 knock-down, 
showed significant time-dependent upregulation with IL4 treatment and no 
significant effect of Trem2 knock-down was observed any more. Also, the 
gene expression of Spi1, Pik3cg, and another two AD-associated microglial 
genes Abi3 and Plcg2 were not significantly affected by Trem2 knock-down 
under the IL4 condition. These data together suggested that the effect of 
Trem2 expression on the microglial gene expression profile might be different 
depending on the activation phenotype of microglia, with higher levels of 
Trem2 expression in response to anti-inflammatory phenotypes, and Trem2 
manipulation modifying the expression of a subset of genes increased with 
anti-inflammatory stimuli.    
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Figure 3.8. TREM2 is involved in the microglial anti-inflammatory response. 
(A) Trem2 gene expression showed a significant time-dependent increase in 
primary microglia with IL4 stimulation. (B) Arg1 and Tgfb1, as markers for the anti-
inflammatory response, showed significant up-regulation with time after IL4 
application. Trem2 KD significantly decreased Arg1 expression compared to 
Control. (C) Expression of the pro-inflammatory gene Il1b was inhibited with time 
after IL4 application; however, KD group was significantly higher than Control. No 
significant difference was observed for the Tnf expression. N= 6 (24 hr) and 4 (48 
hr) independent experiments. Data shown as Mean ± SEM. Two-way ANOVA; 
Significant main effects of IL4 incubation time and Trem2-KD indicated as 
horizontal and vertical lines respectively, no interactions between these two factors 
for all the genes in the figure here; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
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Figure'3.9'
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Figure 3.9. Gene expression changes in primary microglia with IL4 
treatment. C1qa, Cd68, Csf1r, Igf1, Plcg2, and Spi1 expression was found 
to be up-regulated with IL4 (determined by one-sample t-test).  Csf1r was 
significantly lower in KD compared Control. There was also a significant 
interaction between IL4 treatment and Trem2 KD for C1qa expression; 
Sidak’s post hoc tests showed C1qa expression level was significantly 
lower in KD at 48 hr after IL4 application.  
N= 6 (24 hr) and 4 (48 hr) independent experiments. Data shown as Mean 
± SEM. Two-way ANOVA followed by Sidak’s post hoc test if there was 
significant interaction; Significant main effects of IL4 treatment time and 
Trem2-knock-down indicated by horizontal and vertical lines respectively, 
post hoc test significance marked abov individual groups, * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 	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Effects of acute Trem2 knock-down on the cytokine and chemokine 
release of microglia in response to LPS or IL4 
 
In order to identify further and potentially new pathways affected by acute 
Trem2 knock-down on microglial LPS or IL4 induced activation, I used a 
Cytokine Array (a membrane-base sandwich immunoassay that allows us to 
detect a series of cytokines in parallel) to initially screen for cytokines and 
chemokines released from knock-down or control microglia stimulated with 
LPS or IL4. The conditioned culture supernatant samples of the same 
condition were mixed in equal volumes from four independent experiments, 
and performed the array in parallel. The raw data were normalized to the 
western blot signals of GRP75, a housekeeping protein, to account for the 
difference in the cell number among different conditions. With this array, we 
were able to test up to 40 different cytokines, although not all cytokines 
showed detectable signals. A summary of the cytokines / chemokines is listed 
in Table 3.1 and 3.2. What can be noticed is that most of the cytokines tested 
showed much higher levels in response to the LPS than in response to the IL4 
so that they could not be analyzed at the same exposure time. Thus I only 
compared the Trem2-knock-down and control groups with the same 
stimulation.  
 
The cytokine array probed with LPS-treated microglia showed dramatic 
signals of various pro-inflammatory cytokines such as TNF-alpha, CCL5, 
CXCL2, and CXCL10, suggesting the array was working well. The effect of 
Trem2 knock-down on the cytokines released in response to LPS appeared 
modest (Table 3.1). As a control, this cytokine array panel also included TNF-
alpha, for which we saw a 140-150% significant increase in LPS-treated 
Trem2-knock-down microglia versus LPS-treated control microglia using 
ELISA (Figure 3.6), compared to the 1.51-fold increase in TNF-alpha levels in 
the LPS-treated knock-down microglia versus LPS-treated control microglia 
using the cytokine array (Table 3.1), confirming the validity of this cytokine 
array panel. Besides TNF-alpha, we also found a series of cytokine / 
chemokines showing >1.3-fold (but <2-fold) increase in the LPS-treated 
knock-down microglia than the LPS-treated control microglia, such as CCL2, 
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CCL3, CCL4, CCL5, CXCL1, CXCL10, CXCL12, CXCL13, TIMP-1 and IL1-
RA, while other cytokines detected in this condition showed comparable levels 
between knock-down and control groups. As we mixed the n=4 samples in the 
experiment, we could not perform statistics. The next step in these 
experiments would be to perform ELISAs on these top altered cytokines using 
the n=4 samples individually to enable us to confirm the cytokine array results 
using statistics. 
 
As the cytokine signals were consistently much lower in the IL4-stimulated 
microglial medium than the LPS-treated, I had to increase the exposure time 
of detection to obtain analyzable signals. Different from the LPS cohort, I did 
observe more remarkable differences in some of the cytokines between the 
IL4-treated knock-down and the control groups (Table 3.2). The most potently 
increased chemokine was CXCL1, which showed a 6-fold change in the IL4-
treated Trem2 knock-down microglia compared to the IL4-treated control 
microglia. Also, CXCL10 and TIMP-1 production in IL4-treated microglia 
showed substantial difference (around 3-fold) between the knock-down and 
control groups. Furthermore, there was an array of cytokines / chemokines 
showing over 2-fold increase in the knock-down group compared to the 
control, such as CCL5, CXCL2, CXCL12, CXCL13, IL-1α and IL-1RA, and 
over 1.5-fold increase, such as CD54 and CCL2. Some classical pro-
inflammatory markers detected in the LPS condition, such as IL-6, TNFα, and 
G-CSF, were not detectable in the IL4-treated microglia. 
 
In total, my collective data provides strong evidence that acute Trem2 knock-
down affected the microglial cytokine release in response to the anti-
inflammatory factor IL4, while its effects on the LPS-induced cytokine release 
seem relatively modest so far.  
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Table&3.1&
Cytokine/
Chemokine Full name 
Fold change 
(Trem2 KD/Ctrl.) 
CCL5 Regulated)Upon)Ac0va0on,)Normally)T8expressed,)and)Presumably)Secreted;)RANTES 1.66 
CCL2 Monocyte)Chemotac0c)Protein)1;)MCP81 1.63 
CCL4 Macrophage)Inﬂammatory)Protein)18beta;)MIP81β 1.62 
CCL3 Macrophage)Inﬂammatory)Protein)18alpha;)MIP81α 1.58 
CXCL13 B8lymphocyte)ChemoaJractant;)BLC 1.51 
TNFα Tumor)Necrosis)Factor,)Alpha 1.51 
CXCL1 Kera0nocyte8derived)Chemokine;)KC 1.50 
TIMP-1 Tissue)Inhibitor)of)Metalloproteinase)1 1.43 
CXCL12 Stromal)Cell8derived)Factor)1;)SDF1 1.42 
IL-1RA Interleukin)1)Receptor,)Alpha,)Type)I 1.41 
CXCL10 Interferon8gamma8inducible)Protein)10;)IP10 1.36 
IL-1α Interleukin 1-Alpha 1.26 
G-CSF Granulocyte)Colony8s0mula0ng)Factor 1.24 
IL-6 Interleukin 6 1.08 
CXCL2 Macrophage)Inﬂammatory)Protein)2;)MIP2 1.06 
CCL12 Monocyte)Chemotac0c)Protein)5;)MCP85 0.72 
sICAM (CD54) Intercellular)Adhesion)Molecule)1 0.72 
Microglia&with&LPS&for&24&hours&
Table 3.1. Changes caused by acute Trem2 knock-down in the 
cytokine and chemokine secretion in response to LPS stimulation. 
Microglial culture conditioned media samples of the same condition from 4 
independent experiments were equally mixed, and a parallel cytokine array 
was performed to determine the difference between Trem2 KD and Control 
microglia in response to LPS. The fold-change was listed as the average 
intensity of duplicate spots for Trem2 KD relative to Control microglia. 
Cytokines /chemokines with >1.3-fold-change were in red.  
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Table&3.2&
Cytokine/
Chemokine Full name 
Fold change 
(Trem2 KD/Ctrl.) 
CXCL1 Kera%nocyte+derived/Chemokine;/KC 6 
TIMP-1 Tissue/Inhibitor/of/Metalloproteinase/1 3.06 
CXCL10 Interferon+gamma+inducible/Protein/10;/IP10 3.01 
CXCL13 B+lymphocyte/ChemoaCractant;/BLC 2.64 
IL-1α Interleukin 1-Alpha 2.41 
CXCL12 Stromal/Cell+derived/Factor/1;/SDF1 2.38 
CXCL2 Macrophage/Inﬂammatory/Protein/2;/MIP2 2.37 
CCL5 Regulated/Upon/Ac%va%on,/Normally/T+expressed,/and/Presumably/Secreted;/RANTES 2.23 
IL-1RA Interleukin/1/Receptor,/Alpha,/Type/I 2.12 
sICAM (CD54) Intercellular/Adhesion/Molecule/1 1.85 
CCL2 Monocyte/Chemotac%c/Protein/1;/MCP+1 1.64 
CCL12 Monocyte/Chemotac%c/Protein/5;/MCP+5 0.89 
CCL4 Macrophage/Inﬂammatory/Protein/1+beta;/MIP+1β 0.86 
CCL3 Macrophage/Inﬂammatory/Protein/1+alpha;/MIP+1α 0.75 
G-CSF Granulocyte/Colony+s%mula%ng/Factor - 
IL-6 Interleukin 6 - 
TNFα Tumor/Necrosis/Factor,/Alpha - 
Microglia&with&IL4&for&48&hours&
Table 3.2. Changes caused by acute Trem2 knock-down in the 
cytokine and chemokine secretion in response to IL4 stimulation. 
Microglial culture conditioned media samples of the same condition from 4 
independent experiments were equally mixed, and a parallel cytokine array 
was performed to determine the difference between Trem2 KD and Control 
microglia in response to IL4. The fold-change was listed as the average 
intensity of duplicate spots for Trem2 KD relative to Control microglia. 
Cytokines /chemokines with >1.3-fold-change were in red.  
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Summary 
 
This chapter of the thesis focuses on studying two aspects, firstly, identifying 
the cellular functions of TREM2 in regulating different microglial activation 
phenotypes, and secondly, investigating how Trem2 and other important 
microglial factors are regulated in response to pro-inflammatory and anti-
inflammatory factors. I established an in vitro primary microglial model with 
acute Trem2 knock-down via RNAi strategy. I found that acute Trem2 knock-
down induced significant down-regulation of an array of microglial genes, 
such as Igf1 and Csf1r, and impairment of phagocytosis. Furthermore, I 
showed that Trem2 expression was largely down-regulated in microglia with 
the M1 pro-inflammatory stimulus LPS, but up-regulated with treatment with 
the M2 anti-inflammatory cue IL4. Trem2 deficiency produced only a limited 
effect on microglial pro-inflammatory responses, although there was some 
evidence that Trem2 suppressed TNF-alpha secretion in response to LPS. In 
contrast, the M2 alternative phenotype expression in microglia was attenuated 
in Trem2-knock-down microglia. Additionally, Trem2 knock-down also induced 
a higher level of chemokine secretion in response to LPS or IL4, which might 
suggest an increased signaling from microglia for activation and infiltration of 
other cell types such as endothelial cells and peripheral immune cells. Overall 
my data suggest that TREM2 plays an important role in microglial functions in 
inflammation resolution and suppression. In humans, accumulated pro-
inflammatory stimuli might result in prolonged suppressed Trem2 expression 
and function, which leads to a similar influence to that of acute Trem2 knock-
down in the model.  
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Chapter 4 
Microglial gene expressional differences in 
transgenic mouse models of Amyloid-beta 
pathology versus Tauopathy 
 
 
Introduction 
 
The important role of TREM2 in regulating microglial gene expression and 
function in vitro has been investigated. Then the next question would be 
whether microglial Trem2 expression changes in response to different 
components of AD pathology in vivo. In this chapter, I characterized the 
microglial gene expression changes by RT-qPCR in transgenic models of 
amyloid or tau pathology. I particularly investigated the Trem2 gene 
expression related to the Aβ or tau pathology development in these mice. The 
mouse models were described in details in the Methods and Materials 
chapter.  
 
Recent genome-wide association studies have identified a number of gene 
variants that influence AD risk, and are related to microglia. Examples of 
genes that contain SNPs and regulate innate immune cell functions in human 
AD from independent studies are TREM2, CD33, PLCG2 and ABI3 (Griciuc et 
al., 2013; Guerreiro et al., 2013b; Jonsson et al., 2013; Malik et al., 2013; 
Sims et al., 2017), and consistently these genes were also found to show 
significantly increased expression in our previous www.Mouseac.org study in 
the APP/PSEN1 amyloid mouse models as plaques started to deposit 
(Matarin et al., 2015). In our study, we performed microarray and network 
analysis using the same models to examine the gene expression profile 
associated with either Aβ or tau pathology. Trem2 showed strikingly increased 
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expression (around 6-fold) in our amyloid mouse models, and formed a hub 
gene within a network of genes representing the immune system, also 
containing Plcg2, Abi3 and microglial genes like Aif1 and Cd68. The 
expression of this module of immune genes showed an impressive correlation 
of 0.97 with the amyloid pathology, which suggests that Trem2 and the 
module of genes, of which Trem2 is a member, are key drivers of the amyloid 
pathology. The spectacular increase in the expression of this immune module 
in supported by significant increases in the number of microglia in our 
APP/PSEN1 mice by immunohistochemistry. 
 
However, at the time of that study we were not aware that the tau mice 
constituted two lines of mice with different transgene copy numbers and this 
would have increased the variation at any age tested. In this thesis I 
compared amyloid mouse models with different levels of pathology (high 
pathology homozygous APP/PSEN1 mice and medium pathology 
heterozygous APP/PSEN1 mice) to tau mouse models with different levels of 
pathology (high pathology high transgene-copy-number Tau mice and low 
pathology low transgene-copy-number Tau mice), to specifically investigate 
the expression changes of microglial genes in different activation states via 
RT-qPCR.  
 
 
Pathology progression in the mouse models 
 
The amyloid mice used here are two sublines of an APP/PSEN1 mouse 
model – homozygous and heterozygous mice. The HO-APP/PS1 mice start to 
show diffuse amyloid plaques around 2 months, but only from 4 months they 
tend to show true dense-core plaques in the hippocampus (Howlett et al., 
2008; Howlett and Richardson, 2009; Matarin et al., 2015). The plaque 
deposition then further develops, and until 18 months of age most of the HO-
APP/PS1 mouse hippocampus is found covered with a huge amount of Aβ 
deposition (hence high amyloid pathology). The HE-APP/PS1 line (Cummings 
et al., 2015; Matarin et al., 2015) shows a similar but slower pattern of Aβ 
	   78	  
pathology development, with mature plaques starting to development around 
8 months (hence medium amyloid pathology). No obvious neuronal loss is 
reported in this amyloid model, whereas a study from our lab shows early 
synaptic changes (Cummings et al., 2015).   
 
The tau model, TauD35, is a novel tauopathy model generated by 
GlaxoSmithKline (Matarin et al., 2015).  Zelah Joel first characterized the tau 
tangle progression in this model (Joel 2015, PhD dissertation). At 4 months of 
age, neither the low-TAU nor the high-TAU line shows obvious neurofibrillary 
tangles, except some diffuse neuronal soma and processes staining with 
CP13, a phosphorylated tau (specific to phosphorylated serine 202) antibody. 
The high-TAU mice start to show sparse tangles in the hippocampus at 
around 8 months, and the pathology then progresses at an aggressive rate, 
with a heavy tangle load at 12 months and significant neuronal loss and brain 
volume reduction at 18 months (hence high Tau pathology). At around 18 
months they present with severe symptoms such as reduced bodyweight, 
heavy breathing, akinesia, piloerection, and kyphosis, and culled for ethical 
reasons. The low-TAU line, however, only shows very few tangles in the 
hippocampus at 13 months. At 24 months of age, the low-TAU mice do exhibit 
comparable tau tangle burden compared to the 13-month high-TAU, while the 
number of tangles to neurones ratio is lower probably due to the beginning of 
neuronal loss in the 13-month high-TAU mice.  
 
 
Aims 
 
1. To characterize the expression of typical microglial genes (general 
microglial, pro-inflammatory, and anti-inflammatory) in the 
hippocampus along with the Aβ or tau pathology development in the 
transgenic mice by RT-qPCR.   
2. To estimate the average microglial Trem2 expression levels in the 
hippocampus of both models.   
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Results 
Microglial gene expression changes in the hippocampus of wildtype 
mice along with ageing  
 
Before addressing the question of the effects of AD-related pathology, I 
investigated the microglial gene expression changes in the hippocampus of 
wildtype mice along with normal ageing. I studied by RT-qPCR the gene 
expressional levels in the mouse hippocampus of two microglial marker genes 
Aif1 and Cd68, two pro-inflammatory markers Tnf and Il1b, two anti-
inflammatory markers Arg1 and Tgfb1, and one of the recently revealed AD-
associated gene Trem2. As shown in figure 4.1, the most commonly used 
pan-microglial marker Aif1 expression showed a significant increase with 
ageing in the mouse hippocampus (p<0.0001, One-way ANOVA), with a ~3.9-
fold increase at 12 months and a ~2.8-fold increase at 18 months compared 
to that at 4 months (4m vs. 12m, p<0.0001; 4m vs. 18m, p<0.01; 8m vs. 12m, 
p<0.01; Tukey’s post hoc test). Interestingly, I also observed a significant 
decrease of Aif1 expression level from 12 months to 18 months (p<0.05). AD-
associated gene Trem2 also showed significant expression increases with 
ageing (p<0.01), with an increase of ~1.7-fold at 12 months and ~1.9-fold at 
18 months respectively compared to the level at 4 months of age (4m vs. 12m 
and 18m, p<0.01; One-way ANOVA followed by Tukey’s post). Additionally, 
the expression levels of Cd68 (p<0.001), Tnf (p<0.01), and Tgfb1 (p=0.014) in 
the wildtype hippocampus was shown to be increased with age as well, with 
Cd68 starting to show statistic significance from 12 months while Tnf and 
Tgfb1 only showing significance at 18 months. Il1b and Arg1 gene expression 
did not significantly change with age. In general, there was an increase of a 
subset of microglial gene transcripts in the wildtype mouse hippocampus with 
normal ageing that was not specific to certain state of microglia (e.g. pro- or 
anti-inflammatory), which became detectable at around 12 months of age.  
 
Considering that the cDNA used for RT-qPCR analysis was generated from 
the RNA pool of the whole mouse hippocampus that included all cell types, 
the increase of microglial transcripts with ageing might be partially, if not 
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completely, due to an expansion of the microglial population in the 
hippocampus, rather than a simple indicator of microglial gene expression 
profile changes with age. To neutralize this factor to some extent, I used the 
pan-microglial marker Aif1, instead of Rps28 that is expressed by all cell 
types, as the housekeeping gene to re-analyze the RT-qPCR data with the 
assumption that the average Aif1 transcription level shows little change in the 
microglial population with ageing. As in this thesis I was particularly interested 
in Trem2 expression and functional implications, I re-analyzed Trem2 by 
normalizing to Aif1 instead of Rps28 (figure 4.1 B). Interestingly, it was found 
that, there was a significant decrease with age in the Trem2 (normalized to 
Aif1) level in the mouse hippocampus (p<0.0001, One-way ANOVA). Similar 
to the increase of microglial transcripts in the hippocampus with age, this 
decrease started to show statistic significance at 12 and 18 months compared 
to younger ages (4m vs. 12m, p<0.0001; 4m vs. 18m, p<0.01; 8m vs. 12m, 
p<0.01; Tukey’s post hoc). Also there was a slight but significant recovery 
from 12 months to 18 months (p<0.01). Strictly speaking, it is to some extent 
oversimplified to use this approach to analyze the microglial gene expression, 
as in the brain microglia may show various subgroups with different gene 
expressional signatures and thus different functional phenotypes. But still, 
such decrease with age might suggest 1) Trem2 expression decreases in 
each single microglial cell with age, 2) a reduced proportion of microglia with 
substantial Trem2 expression compared to other microglial phenotypes with 
relatively low Trem2 expression, or 3) a difference in the Aif1 expression level 
between microglia. Additionally, the recovery of the Trem2/Aif1 ratio from 12 
months to 18 months also appeared interesting, which might need follow up to 
further investigate.  
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Figure 4.1. Increase of microglial gene transcripts in wildtype mouse 
hippocampus with normal ageing. (A) Significantly increased transcript 
levels of various microglial genes with ageing in wildtype mouse 
hippocampus were observed, as measured by RT-qPCR and normalized to 
a housekeeping gene Rps28. (B) Trem2 transcript level (as measured by 
RT-qPCR and normalized to Rps28) showed a significant increase in 
wildtype hippocampus with ageing as well; However, when normalized to a 
pan-microglial marker gene Aif1, Trem2 expression showed a significant 
decrease with ageing.  
N=4 (4 months), 3 (8 months), 8 (12 months), and 7 (18 months) mice. 
Data shown as Mean ± SEM. One-way ANOVA followed by Tukey’s post 
hoc tests if there was significant interaction, * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001.  
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Microglial gene expression changes in the amyloid or tau pathology 
mouse models  
 
In order to investigate the microglial gene expression at different stages of Aβ 
or tau pathology, I employed two amyloid model lines of different pathology 
progression rates (homozygous and heterozygous APP/PSEN1 mice) and two 
TauD35 lines (high-transgene-copy (high-TAU) and low-transgene-copy (low-
TAU) mice), with the wildtype data shown in figure 4.1 as the age-matched 
control. Again I analyzed the same microglial genes with the previous section 
by RT-qPCR. As shown in figure 4.2 A, Aif1, Cd68, and Trem2 all showed 
increased expression in the hippocampus of the mouse models along with 
pathology progression (significant main effects of both Genotype and Age and 
interaction; Two-way ANOVA followed by Tukey’s post hoc tests). Specifically, 
for the amyloid models, HO-APP/PSEN1 mice started showing significant 
increase compared to age-matched wildtype mice from about 8 months (the 
stage when mature amyloid plaques developed), which further kept rising with 
age; while in HE-APP/PSEN1 the significant increase started to be evident 
from 12 months, corresponding to a slower rate of Aβ deposition than HO-
APP/PSEN1. For the tau model, the up-regulation of these genes started to 
be significant from 12 months in high-TAU mice, while there was no significant 
difference from the wildtype across all age groups in low-TAU mice. 
Particularly, the high-TAU mice showed consistently significantly lower Trem2 
levels than the HO-APP/PSEN1 mice across 8-18 months of age. Then I 
analyzed pro-inflammatory genes Tnf and Il1b expression levels in the models 
(figure 4.2 B). These two genes also showed significant changes among 
different ages and genotypes, and a significant interaction allowing us to 
perform post hoc tests. For the amyloid models, significant increase of Tnf 
expression was only observed in the homozygous mice, starting from 12 
months and maintaining statistical significant until 18 months, the Il1b 
expression was not significantly different from the wildtype though. For the tau 
models, again only high-TAU but not low-TAU showed significant increased 
Tnf and Il1b expression at 12 months and 18 months. Particularly, the Il1b 
expression in the 18-month high-TAU was significantly higher than the HO-
APP/PSEN1 mice (p<0.01), although the Tnf expression level was not 
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significantly different between these two genotypes. Additionally, the fold 
changes of these two pro-inflammatory genes in the mouse models versus 
wildtype appeared to give a lot of variation among mice, e.g. the Tnf 
expression in 12-month HO-APP/PSEN1 mice was about 3-10 fold of that in 
age-matched wildtype mice, and 5-48 folds at 18 months of age, suggesting a 
high inter-animal variability with respect to the inflammatory states in the 
brain. Next we tested anti-inflammatory genes Arg1 and Tgfb1 expression 
(figure 4.2 C). Arg1 did not show significant changes across ages or 
genotypes by Two-way ANOVA. Tgfb1 did show significant main effects of 
both age (p<0.0001) and genotype (p<0.01), but no significant interaction. 
Taken together, both Aβ and tau pathology development induced increased 
microglial transcripts in the mouse hippocampus, although this might be due 
to an expansion of microglial population. Also, the tau mice at late stage of 
pathology appeared to show higher pro-inflammatory gene expression, such 
as Il1b, than the amyloid mice at the same age. 
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Figure 4.2. Changes of microglial gene transcripts in the hippocampus of amyloid or 
tau mouse models with age. (A) Significant gene expression increase of Aif1, Cd68 and 
Trem2 compared to age-matched wildtypes (same data with figure 4.1) was observed in 
both amyloid and tau models. (B) Significant Tnf expression was observed in HO-
APP/PSEN1 and high-TAU mice at relatively middle-late stages of the pathology 
progression, while the Il1b expression was only found to be significantly higher in the high-
TAU line at middle-late stages. (C) Time-dependent increased Tgfb1 expression in both 
types of models without significant interaction between genotype and age. No significant 
change in Arg1 expression between models and wildtypes.  
N=3-8 (wildtype), 3-4 (HE-APP/PSEN1), 3-5 (HO-APP/PSEN1), 3-4 (low-TAU), and 3-6 
(high-TAU) mice per group. Data shown as Mean ± SEM. Two-way ANOVA followed by 
Tukey’s post hoc test if there was significant interaction; horizontal and vertical lines for 
significant main effects of age and genotypes respectively, * for post hoc test significance 
HE-APP/PSEN1 versus WT, ♯ for HO-APP/PSEN1 versus WT, $ for high-TAU versus WT, 
and £ for high-TAU versus HO-APP/PSEN1.   
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To neutralize the influence of the microglial population expansion, I again re-
analyzed Trem2 expression by normalizing to Aif1 rather than Rps28 (figure 
4.3 A). Two-way ANOVA showed that both the age and genotype had 
significant main effects on the Trem2 (normalized to Aif1) levels in the mouse 
hippocampus (p<0.0001), and also there was a significant interaction between 
the two factors (p<0.01) suggesting a genotype-dependent Trem2 expression 
pattern with age. Further Tukey’s post hoc tests suggested that only the Aβ 
models, but not the tau models, exhibited significantly increased Trem2 
compared to age-matched wildtype mice, with HO-APP/PSEN1 and HE-
APP/PSEN1 starting around 8 and 12 months respectively and maintaining 
until at least 18 months. Additionally, high-TAU mice at 4 months showed 
significant lower Trem2 than the wildtype (p=0.011), which gradually 
normalized with ageing but still significantly lower than age-matched 
APP/PSEN1. As a comparison, the Cd68 expression was re-analyzed by 
normalizing to Aif1 as well (figure 4.3 B). Different from Trem2, although there 
were significant main effects of genotype (p<0.01) and age (p<0.0001), no 
significant interaction was observed by Two-way-ANOVA, suggesting the 
changing pattern of the magnitude differences between genotypes compared 
to the wildtype with age was not significantly different between the Aβ and tau 
models. Overall, the results suggest a highly up-regulated microglial Trem2 
expression in the amyloid model as the Aβ deposition developed, despite the 
increased microglial number in the hippocampus. However, in the tau mice, I 
did not observe convincing Trem2 increase relative to the Aif1 levels, possibly 
suggesting a lack of Trem2 up-regulation in the context of individual microglial 
cell. 
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Figure 4.3. Microglial Trem2 and Cd68 expression relative to Aif1 
levels in the hippocampus of amyloid or tau mouse models. (A) Trem2 
(normalized to Aif1 rather than Rps28) expression in each mouse 
hippocampus was analyzed and showed a significant increase relative to 
the WT in the amyloid models along with pathology development, but not in 
the tau models. However, at 4 months of age high-TAU exhibited a 
significant lower Trem2 expression compared to the WT. (B) Significant 
changes of the Cd68 (normalized to Aif1) expression among ages 
(p<0.0001) or genotypes (p<0.01), while no significant difference in the 
changing pattern between amyloid and tau models was found. Two-way 
ANOVA followed by Tukey’s post hoc tests if there was significant 
interaction between age and genotype effects. 
N=3-8 mice per group. Data shown as Mean ± SEM. Two-way ANOVA 
followed by Tukey’s post hoc test; horizontal and vertical lines for significant 
main effects of age and genotypes respectively, * for post hoc test 
significance HE-APP/PSEN1 versus WT, ♯ for HO-APP/PSEN1 versus WT, 
$ for high-TAU versus WT, and £ for high-TAU versus HO-APP/PSEN1.   
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Summary 
 
I characterized the expression of a series of microglial genes in the 
hippocampus of the amyloid and tau models by RT-qPCR. An increase of 
microglial gene transcripts (Aif1, Cd68, Trem2, Tnf, and Tgfb1) with ageing 
was found in the hippocampus of the wildtype mice, potentially suggesting 
increased microglial number and/or increased microglial activation with 
normal ageing. Furthermore, referring to the time course of pathology 
development in these models previously reported from our group (Cummings 
et al., 2015; Matarin et al., 2015; Joel 2015, PhD dissertation), the general 
microglial genes transcripts increased closely following the amyloid plaque 
progression in the amyloid mice, while in the tau mice it was relatively delayed 
compared to the tangle development. With respect to the pro-inflammatory 
genes, they only showed significant upregulation at late stages of established 
pathology in both types of models. Especially for Il1b, its level in 18-month 
high-TAU was significantly higher than age-matched HO-APP/PSEN1. More 
importantly, although increased Trem2 transcripts were observed in the 
hippocampus of both models, different models showed significantly different 
Trem2 expression when it was normalized to microglial marker gene Aif1 to 
neutralize the influence of the microglial number changes in the hippocampus. 
The Trem2 level normalized to Aif1 was highly increased with age in the 
amyloid mice compared to the tau model and the wildtype, suggesting a 
highly upregulated microglial Trem2 expression specifically induced in the 
amyloid mice with pathology development.   
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Chapter 5 
Microglial similarities and differences in 
transgenic mouse models of Amyloid-beta 
pathology versus Tauopathy – Histology 
 
 
Introduction 
 
Accumulated and activated microglia are important features of AD pathology, 
which has been described in both human patients and transgenic mouse 
models.  Highly up-regulated MHC-II (HLA-DR) expression in the microglia, 
especially those accumulating in the vicinity of amyloid plaques in human AD 
brains (Itagaki et al., 1989; McGeer et al., 1987; Perlmutter et al., 1992; 
Rogers et al., 1988; Styren et al., 1990), particularly indicates an activated 
phenotype in response to Aβ pathology of AD. In addition to the interaction 
between microglia and plaques, the microglial interaction with tau pathology 
has recently started being investigated as well, while the relationship between 
microglia and tau pathology remains to be further studied. In vitro research 
has shown that both tau oligomers and fibrils can induce microglial activation 
and promote pro-inflammatory cytokine production (Morales et al., 2013). 
Consistently, in a tau (P301S) mouse model microglial activation was 
observed before neurofibrillary tangles developed (Yoshiyama et al., 2007), 
suggesting a role of pre-tangle tau species in activating microglia. More 
importantly, activated microglia appear to promote the onset and progression 
of tau pathology in a human tau mouse model (Maphis et al., 2015), which 
might suggest a potential link between Aβ pathology and tau pathology in AD 
progression. 
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In chapter 4, I have characterized the microglial gene expression in our 
amyloid models and tau models, in which it was showed a more closely 
associated microglial genes up-regulation with Aβ pathology and a potential 
difference in the microglial Trem2 expression regulation between the amyloid 
and tau models. Additionally, I observed a potentially more pro-inflammatory 
state in the tau model than the amyloid model at the stage when both 
expressed high load of pathology. In this chapter, by immunohistochemistry, I 
further characterized the microglial proliferation and activation in different 
regions of the hippocampus of mice exhibiting different pathology stages, with 
a particular emphasis on analyzing the similarities and differences between 
the amyloid mice and the tau mice.  
 
Unfortunately, I did not manage to find a mouse TREM2 antibody with high 
specificity. I tested in total 4 commercially available TREM2 antibodies with 
our Trem2-knocked-down BV2 cell samples by Western blot, none of which 
showed sufficient specificity.  
 
 
Aims 
 
1. To investigate the microglial expansion/proliferation and activation in 
different regions of the hippocampus related to the pathology in the 
models by immunohistochemistry.   
2. To compare and contrast the microglial parameters between the 
amyloid and the tau models.  
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Results 
 
Microglial activation in the hippocampus of an APP/PSEN1 mouse 
model  
 
In order to characterize further microglial proliferation and activation in AD-
related mouse models I used immunohistochemistry. Here I immune-stained 
serial sections (30µm thick, around 720µm apart, transverse to the 
hippocampus) from frozen-fixed brains of HO-APP/PSEN1 and wildtype mice 
at 4 and 12 months, which represented the early and late stages of the Aβ 
deposition, with CD68 and IBA1 targeting antibodies. IBA1 (ionized calcium 
binding adaptor molecule 1), which is encoded by gene Aif1 and in the brain is 
specifically expressed in microglia (Imai et al., 1996; Ito et al., 1998), is widely 
used as a marker for all microglia regardless of activation. CD68 (macrosialin) 
is a lysosomal glycoprotein highly expressed by monocytes and tissue 
macrophages (Holness and Simmons, 1993; Saito et al., 1991), and is 
commonly used as a marker for microglial phagocytic activities.  
 
To quantify the total microglia in the dentate gyrus (DG) and CA1 regions of 
hippocampus I produced a z-stack image using confocal microscopy (figure 
5.1). As shown in figure 5.1 C, IBA1-positive cells, representing the whole 
microglial population, showed a significant increased number (around 5-fold 
change) in 12 month HO-APP/PSEN1 DG (p<0.0001) and CA1 (p<0.001) 
regions compared to age-matched wildtype mice (Two-way ANOVA followed 
by Tukey’s post hoc tests). Also, I noticed that the microglia number in both 
DG and CA1 of the 4-month HO-APP/PSEN1 was actually ~2-fold of that in 
the wildtype; although no statistic significance was obtained (in DG, p=0.86; in 
CA1, p=0.33), probably due to a small sample size (n=2 for 4-month HO-
APP/PSEN1) and thus lack of statistic power, it still retained the possibility of 
a potential increase in the microglia number in the HO-APP/PSEN1 mice at 
this age.  
 
I further quantified the CD68-positive cells in the same regions of the brain. I 
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observed a proportion of microglia (IBA1-positive cells) with obvious CD68, 
mainly represented as spreading or clustered or vesicular signals in the 
cytoplasm or closely underneath the cell membrane. Quantification showed 
that both DG (p<0.001) and CA1 (p<0.01) regions had significantly more 
CD68-positive microglia in 12-month HO-APP/PSEN1 mice than wildtype 
mice (Two-way ANOVA followed by Tukey’s post hoc tests). At 4 months of 
age, I did not observe a significant difference between HO-APP/PSEN1 and 
wildtype mice. As the total microglial number increased significantly in the 12-
month HO-APP/PSEN1 model, the increased number of CD68-positive 
microglia was not surprising. Next, to further understand the phenotype 
change of microglia at the cellular level, I analyzed whether the percentage of 
CD68-positive microglia in the whole microglial population also changed in the 
HO-APP/PSEN1 compared to the wildtype (figure 5.1 D). Two-way ANOVA 
suggested that there was no significant difference between HO-APP/PSEN1 
and wildtypes; however, the age did exhibit a significant main effect (in DG, 
p=0.034; in CA1, p=0.0012), with significantly increased percentage of CD68-
positive microglia in the 12-month mice compared to 4-month mice in both DG 
and CA1 hippocampal regions. Overall, the HO-APP/PSEN1 mice showed 
significant expansion of the microglial population in the hippocampus, 
following the amyloid plaque deposition. The percentage of activated CD68-
positive microglia in the total microglial population showed an age-dependent 
increase in the hippocampus, while there was no significant difference 
between wildtype and HO-APP/PSEN1.  
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Figure 5.1. Microglial activation in the hippocampus of the amyloid 
mouse model.  (A) Left panel: An overall low-magnification image to show 
the transverse hippocampus of a 12-month HO-APP/PSEN1 mouse. The 
white boxes showed the areas of interest employed for confocal imaging 
and quantification. Scale bar: 200µm. Right panel:  Representative CD68+ 
microglia and CD68- microglia. Scale bar: 10µm. (B) Representative 
images of hippocampal dentate gyrus and CA1 regions in the brain 
sections from 4- and 12- month HO-APP/PSEN1 and wildtype mice double 
stained using IBA1 (green) and CD68 (red), imaged with confocal 
microscopy and quantified with ImageJ. Scale bar: 50µm. (C) Significantly 
higher numbers of both total microglia (determined by IBA1+ cells) and 
CD68+ microglia were observed in the HO- APP/PSEN1 mice at 12 months 
compared to the wildtype. (D) The percentage of CD68+ microglia in the 
total microglial population showed no significant difference between the WT 
and HO- APP/PSEN1, but there was a significant increase with age.  
N=3 mice per group, except for 4-month HO-APP/PSEN1 with n=2 (3 
sections per mouse). Data shown as Mean ± SEM. Two-way ANOVA 
followed by Tukey’s post hoc test if there was significant interaction; 
horizontal and vertical lines for significant main effects of age and 
genotypes respectively, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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To further investigate the activation status of microglia, I studied mouse MHC-
II expression in the APP/PSEN1 mouse model versus the wildtype. MHC-II 
(Major Histocompatibility Class II) molecules generally present antigens to 
immune cells, which thus elicit adaptive immune responses, and the MHC-II 
up-regulation in microglia accompanies more pro-inflammatory activation. I 
first tested co-staining of IBA1 and mouse MHC-II in the brain sections of HO-
APP/PSEN1 and wildtype mice, and found all MHC-II positive cells found in 
the brain parenchyma were IBA1-positive as well (figure 5.2 A), suggesting 
MHC-II was predominantly expressed by brain-resident microglia/ 
macrophages, and perhaps peripherally infiltrated myeloid cells, if any. I 
investigated the MHC-II expression in the hippocampus across different ages 
by immunohistochemistry. Surprisingly I found that, in the wildtype mice even 
at very old ages (30 months), there was no detectable MHC-II staining in the 
brain parenchyma, except a group of positive cells found in the choroid 
plexus. However, in both homozygous and heterozygous APP/PSEN1 brains, 
I did observe a subgroup of microglia with substantial MHC-II signals, which 
started from around 12 months of age and particularly, only represented a 
small proportion of the total microglia (figure 5.2 B). Additionally, there was a 
high inter-animal variability in the number of MHC-II-positive microglia in the 
brain, and between the 12-month HO- and HE- APP/PSEN1 mice, which 
exhibited a substantial difference in the amyloid plaque load, quantification of 
the MHC-II positive microglia in the whole hippocampus did not show a 
significant difference (student t-test).  
 
In total, it suggests that there is significant expansion of microglia in the 
amyloid mouse models, which is probably due to increased proliferation of 
microglia in response to Aβ deposition. However, the ‘activation’ phenotype of 
the microglial population does not seem to have a comparable change relative 
to the level of microglia number increase, as represented by unchanged 
proportion of CD68-positive microglia and only a small group of MHC-II 
positive microglia at the middle-late stages of Aβ deposition.  
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Figure 5.2.  MHC-II expression in the hippocampus of APP/PSEN1 mice at 12 months. 
(A) IBA1 and MHC-II double-staining showed a subgroup of microglia (IBA1+) were MHC-
II+ in the brain parenchyma of the 12-month APP/PSEN1 mice. All MHC-II+ cells were also 
IBA1+. Scale bar: 50µm. (B) Top: Representative images showing microglia expressing 
MHC-II in the whole hippocampus. MHC-II was not observed in the brain parenchyma of 
WT mice except in the choroid plexus. 4-month and 12-month HE- and HO- APP/PSEN1 
were analyzed and MHC-II expression in the brain parenchyma was only observed in the 
12-month mice. The distribution showed a random pattern without obvious association with 
plaques. The area in the orange box was zoomed to show examples of MHC-II+ microglia 
(white arrows) and plaque area (the hole-like area without DAPI, indicated with yellow 
arrows). Scale bar: 200µm. Bottom: Comparison of the MHC-II+ microglial number in the 
area of the whole hippocampus between 12-month HE- and HO- APP/PSEN1 mice. No 
significant difference was found (Unpaired Student t-test). N=3 mice per group (3 serial 
sections (around 720µm apart) per mouse). Data shown as Mean ± SEM.  
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Microglial changes in the hippocampus of a tau model 
  
Next I studied the microglia number and activation by immunohistochemistry 
in the TauD35 mouse models. I employed the high-TAU and low-TAU mice 
with wildtype mice at the ages of 4 and 12 months. Again I first investigated 
the IBA1 and CD68 expression in the hippocampus of the brain (figure 5.3). 
Quantification of total microglia (IBA1-positive) showed that in both DG and 
CA1 regions of the hippocampus, both the transgene copy number (DG, 
p<0.001; CA1, p<0.01) and the age  (DG, p<0.0001; CA1, p<0.001) exhibited 
significant main effects on the microglia number, with a significant interaction 
as well (DG, p<0.001; CA1, p<0.01; Two-way ANOVA). Tukey’s post hoc 
tests suggested a significantly increased microglia number in the 
hippocampus of the 12-month high-TAU mice than age-matched wildtypes 
(DG, p<0.0001; CA1, p<0.01), while no significant difference was observed 
between 4-month high-TAU and wildtype mice or between 12-month low-TAU 
and wildtype mice. In terms of CD68-positive microglia, I observed a similar 
pattern of changes to the IBA1 quantification in the TAU model. There were 
significant effects of both the transgene copy number (DG, p<0.0001; CA1, 
p<0.001) and the age (DG, p<0.0001; CA1, p<0.0001) that showed a 
significant interaction as well (DG, p<0.0001; CA1, p<0.001; Two-way 
ANOVA). Following Tukey’s post hoc tests showed again a significant 
increase of CD68-positive microglia in the hippocampus of the 12-month high-
TAU mice (p<0.0001 in both DG and CA1). Again, I analyzed the percentage 
of CD68-positive microglia in the total microglial population (figure 5.3 D). In 
both DG and CA1 regions of the hippocampus, I observed a significant 
increase in the CD68-positive microglia proportion with age regardless of the 
genotype (both DG and CA1, p<0.0001; Two-way ANOVA), which was 
consistent with our previous results for the APP/PSEN1 section. However, 
different from the Aβ model, I did find a significantly elevated CD68-positive 
microglia proportion in the TAU model than the wildtype (DG, p=0.03, CA1, 
p=0.06 (trend); Two-way ANOVA), which seemed more evident in the 12-
month high-TAU compared to the wildtype.   
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Figure 5.3. Microglial activation in the hippocampus of the tau model.  
(A) Left panel: An overall low-magnification image to show the transverse 
hippocampus of a 12-month high-TAU mouse. The white boxes showed the 
areas of interest employed for imaging and quantification. Scale bar: 
200µm. Right panel:  Representative CD68+ microglia and CD68- 
microglia. Scale bar: 10µm.  (B) Representative images of hippocampal 
dentate gyrus and CA1 regions from 4 and 12 months wildtype, low-TAU, 
and high-TAU mice, stained with IBA1 (green) and CD68 (red), imaged with 
an epifluorescent microscope and quantified with ImageJ. Scale bar: 50µm. 
(C) Significantly higher numbers of both total microglia (determined by 
IBA1+ cells) and CD68+ microglia in the high-TAU mice at 12 months 
compared to the wildtype. (D) The percentage of CD68+ microglia in the 
total microglial population was compared between genotypes and ages. 
Both the age and the transgene copy number showed significant main 
effects.  
N=3 mice per group except for the 12-month high-TAU and 12-month low-
TAU with n=2 (3 sections per mouse). Data shown as Mean ± SEM. Two-
way ANOVA followed by Tukey’s post hoc test if there was significant 
interaction; horizontal and vertical lines for significant main effects of age 
and genotypes respectively, * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. 
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I then examined the pro-inflammatory MHC-II expression in the tau models as 
well. At 4 months of age, neither high-TAU nor low-TAU mice showed 
detectable MHC-II in the brain parenchyma by immunohistochemistry. 
However, at 12 months, high-TAU mice showed a group of MHC-II positive 
microglia in the hippocampus and cortex, while the low-TAU at 12 months still 
showed no detectable MHC-II positive microglia (figure 5.4 A). Importantly, 
the distribution of this group of MHC-II positive microglia in the hippocampus 
was distinct compared to the Aβ model, with a substantial number of cells 
accumulated in the stratum lacunosum-moleculare (SLM) layer adjacent to 
the hippocampal sulcus. Additionally, I immuno-stained with MHC-II antibody 
in the 24-month low-TAU mice to investigate whether they would show MHC-II 
signals in the brain at this stage, and I did observe a subgroup of microglia 
that were MHC-II positive. The 24-month low-TAU mice showed comparable 
tau tangle number in the hippocampus to the 12-month high-TAU; however, 
there was a potential but not statistically significant neuronal loss in the 12-
month high-tau mice that was not observed in the 24-month low-TAU (Joel, 
PhD dissertation 2015). We thus proposed that these stages represented the 
potential period of the progression from tauopathy to neurodegeneration. 
Comparison between the 12-month high-TAU and 24-month low-TAU showed 
a strong trend of a significantly higher number of the MHC-II positive microglia 
in the 12-month high-TAU (figure 5.4 B; p=0.056, Student t-test), although the 
sample size was low and further clarification is necessary.  
 
In total, microglial expansion and activation in the hippocampus was observed 
in 12-month high-TAU that was at the stage with severe tau tangle 
development. Different to the amyloid model, the tau mice not only showed a 
strong increase in the total microglial number, but also a significant increase 
in the proportion of CD68-positive microglia (representing high phagocytic 
activity and widely used as a marker for microglial activation). In addition, the 
MHC-II positive microglial/myeloid cells that were evident in both amyloid and 
tau models at middle-late stages, showed a particularly different distribution in 
the tau mice from the APP/PSEN1 model.  
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Figure 5.4.  MHC-II expression increase in the hippocampus of 24-
month low-TAU and 12-month high-TAU mice. Top: Representative 
images showing microglia expressing MHC-II in the hippocampus. MHC-II 
expression was investigated using immunohistochemistry in 4-, 12-, and 24-
month old mice. MHC-II staining was visible from 12 months in high-TAU 
mice and 24 months in low-TAU mice. The MHC-II+ microglia tend to have a 
higher density in the stratum lacunosum-moleculare (SLM) region. Scale 
bar: 200µm. Bottom: Comparison of the MHC-II+ cell number between 24-
month low-TAU and 12-month high-TAU mice in the total hippocampus. 
N=2-3 mice per group (3 sections per mouse). Data shown as Mean ± SEM. 
Unpaired student t-test; p=0.056.  
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Microglial expansion in different layers of the hippocampal CA1 region 
in the tau mice 
 
As the MHC-II positive cells in the tau model showed an accumulation in the 
CA1 SLM layer, I wondered whether the total microglial distribution amongst 
different regions of the hippocampus was changed in different mouse models. 
I analyzed the microglia number by IBA1 staining in different layers of the 
hippocampal CA1 region in the wildtype, HO-APP/PSEN1, HE-APP/PSEN1, 
high-TAU, and low-TAU mice at 12 months of age (figure 5.5). I did observe a 
significant interaction between the effects of different genotypes and different 
CA1 layers (genotype, p<0.0001, CA1 layer, p<0.0001, interaction, p<0.001; 
Two-way ANOVA followed by Tukey’s post hoc test). Specifically, the HO-
APP/PSEN1 showed dramatic increase of microglial number in all four CA1 
layers compared to the wildtype. The HE-APP/PSEN1 mice at this age only 
showed significantly increased microglia number in the SLM and SR (stratum 
pyramidale) layers, with a level falling between the homozygous line and the 
wildtype. However, regarding the high-TAU mice, a significant increase in the 
microglial population was only observed in the SLM layer, with an over 2-fold 
level of that in the wildtype mice. Additionally, there was a strong trend 
towards a significant increase in the SO (stratum oriens) layer in the high-TAU 
versus the wildtype (p=0.055). Taken together, the microglial distribution in 
the amyloid mice mainly depends on the plaque deposition (as shown by 
clustered microglia around plaque-like areas), and thus in the HE-APP/PS1 
mice at 12 months, a higher microglia number was shown in the layers where 
plaques first develop in the CA1 region. However, in the tau model, there is a 
dramatic higher microglial density in the SLM layer where the perforant 
pathway fibers from the entorhinal cortex form synapses with the CA1 
pyramidal neurons.  
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Figure 5.5. Microglial distribution in the hippocampal CA1 layers of the 
amyloid model and the tau model at 12 months. Upper: Representative 
images showing microglia by IBA1 staining in the CA1 region of the 
hippocampus. The layers from top are SO (stratum oriens), SP (stratum 
pyramidale), SR (stratum radiatum) and SLM (stratum lacunosum-
moleculare). Scale bar: 50µm. Lower: Significantly increased microglial 
density in all 4 CA1 layers in the HO-APP/PS1, in the SR and SLM regions 
in the HE-APP/PS1, and in the SLM layer in the high-TAU mice. N=2-3 
animals per group (3 sections per mouse). Data shown as Mean ± SEM. 
Two-way ANOVA followed by Tukey’s post hoc test if there was significant 
interaction; horizontal and vertical lines for significant main effects of layers 
and genotypes respectively, * p<0.05, *** p<0.001, **** p<0.0001.  
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Summary 
 
Both models showed obvious microglial expansion along pathology 
development using immunohistochemistry. However, the activation phenotype 
seemed different between the amyloid and the tau models. First, there was a 
significant increase in the CD68-positive microglial proportion in the tau 
models compared to the wildtype, while the amyloid mice only showed 
expansion of the total microglial population. Second, in the tau mice there was 
more substantial MHC-II expression in the hippocampus. The amyloid mice 
did show MHC-II positive cells as well, but it was only a very small group of 
cells, especially considering the highly increased microglial population at that 
stage. Third, the distribution of microglia in the hippocampus changed in the 
tau mice, with much higher microglial density in the SLM layer of CA1 region, 
while the microglial density in the SP region, mainly with CA1 pyramidal 
neuronal cell bodies where tau tangles accumulate, did not show much 
changes compared with the wildtype. Importantly, these similarities and 
differences in microglial numbers, activation and hippocampal regional 
localization provide us with important information on how microglia respond to 
different aspects of pathology associated with Alzheimer’s disease, and how 
microglia may contribute to the pathology.  
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Chapter 6 
Discussion 
 
 
Alzheimer’s disease, the most common cause of dementia, threatens society 
at many levels with its particular difficulty of long progression, late diagnosis 
and lack of effective intervention. Recently, GWAS studies uncovering a 
variety of immune-related gene variants as AD risk factors, such as TREM2, 
CD33, ABI3, and PLCG2 (Griciuc et al., 2013; Guerreiro et al., 2013b; 
Hollingworth et al., 2011; Jonsson et al., 2013; Malik et al., 2013; Naj et al., 
2011; Sims et al., 2017), have placed a spotlight on the potential role of the 
innate immune system especially the brain resident microglia in AD 
pathogenesis. In particular, TREM2, a myeloid cell transmembrane protein 
only first identified in the early 21st century and revealed as one of the 
strongest AD risk genes, still retains secrecy for its precise biological 
functions. But it is likely to perform a regulatory role for microglia, which 
requires intensive studies to reveal its functions and contributions to AD, as 
well as allowing us to understand enough of the driving mechanisms to enable 
effective drug targeting.  
 
In this thesis, I have focused on the cellular functions of TREM2 in microglia, 
using an in vitro primary microglial model with acute Trem2 knockdown by 
RNAi strategy. This approach can readily be applied to study the many other 
microglial-expressed genes recently discovered to be associated with AD and 
other neurodegenerative conditions. In the past few years, there have already 
been a variety of in vitro studies that have shed light on some aspects of the 
TREM2 biological functions on microglia or macrophages, and the most 
promising conclusion is about the involvement of TREM2 in phagocytosis and 
restricting inflammatory responses (as discussed in Chapter 1). In chapter 3 
of this thesis, I not only further validated the effects of Trem2 deficiency on 
these functions in a physiologically relevant system, primary microglia, but I 
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also particularly studied its effects on general microglial gene expression and 
microglia polarized to the M2 alternative activation phenotype, also known as 
‘anti-inflammatory and tissue repairing’ functions. Particularly, my results 
suggest that TREM2 is involved in regulating the microglial IL4 signaling 
pathway that further up-regulates Trem2 expression, which could be an 
important pathway interacting with the TREM2 signaling in microglia and a 
potential drug-targeting pathway for compensating TREM2 deficiency. Further 
investigation on potential downstream steps influenced by TREM2 is needed. 
Additionally, I employed the primary microglial culture from wild type mice and 
induced acute Trem2 knockdown after the microglia developed normally in 
vivo, allowing us to study more direct functions of TREM2, not diluted by 
compensatory changes that may occur during chronic Trem2 inhibition, as in 
Trem2 knock-out studies.  
 
Secondly, in chapter 4 and 5, I utilized two lines of transgenic mouse models 
that mimic either the amyloid or the tau pathology development of AD, to 
investigate the differences in microglial phenotypes in the context of different 
aspects or stages of AD pathogenesis. By studying this topic, I have furthered 
the importance of targeting differential microglial pathways and functions 
depending on the different time points of therapeutic intervention in AD. 
Particularly, I have emphasized divergent microglial Trem2 expression 
changes in response to amyloid or tau pathology in these mice, which enables 
us to analyze the dynamic and multiple contributions of TREM2 implicated in 
AD pathology progression.  
 
 
Trem2 gene expression divergently regulated by microglial 
inflammatory states in vitro 
 
I found Trem2 expression was differentially regulated under different 
microglial inflammatory conditions in our in vitro model. In steady-state 
microglia, without either LPS or IL4 treatment, Trem2 expression was 
consistently detected in our primary microglial model, although there was a 
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substantial variation in the expression levels between different preparations of 
cells, which might reflect biological variability between different litters of mice 
and differences in the microglial status due to a technical variation during 
experiment. With LPS stimulation, our model exhibited a robust pro-
inflammatory response, as measured by strong up-regulation of Tnf and Il1b, 
and importantly, Trem2 gene expression was largely suppressed, which 
started between 3 and 6 hours after LPS application and quickly reached 
>90% decrease by 24 hours. This finding is consistent with previous studies 
showing that LPS down-regulated Trem2 expression in microglia or 
macrophages in vitro and in vivo (Owens et al., 2017; Schmid et al., 2002; 
Turnbull et al., 2006; Zheng et al., 2016). Moreover, Owens and colleagues 
showed that treatment with pro-inflammatory mediators engaging other TLRs, 
rather than TLR4, which is recognized by LPS, also suppressed Trem2 
expression in the BV2 cell line, albeit with slight different potency (Owens et 
al., 2017). This suggests that the Trem2 down-regulation is not specific to 
LPS-TLR4 signaling but perhaps a common event occurring in microglial 
classical activation induced by various pro-inflammatory stimuli. 
 
Mechanistically, it was found that LPS-induced Trem2 down-regulation in the 
BV2 cell line was dependent on activation of NF-κB (Owens et al., 2017; 
Zhong et al., 2017b). I found in the in vitro model that the Trem2 
transcriptional suppression started between 3 and 6 hours after LPS 
treatment, which occurred later than up-regulation of pro-inflammatory genes 
Tnf and Il1b that are directly regulated by NF-κB activation. The suppression 
of Trem2 expression might thus be through an indirect regulatory mechanism 
of NF-κB. Scientists have already found that Trem2 expression was 
suppressed by miRNA-34a that was induced by NF-κB (Alexandrov et al., 
2013; Bhattacharjee et al., 2016; Zhao et al., 2013). Therefore, negative 
regulation of Trem2 expression might be one of the modulating mechanisms 
of microglia to adjust to various functional requests. 
 
In contrast to LPS, IL4 stimulation that induces typical M2 alternative 
activation, involved in inflammation suppression and tissue repair, resulted in 
up-regulation of Trem2 expression in the in vitro model. I noticed a consistent 
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increase (to around 150% levels of non-treated cells) in the Trem2 
transcriptional levels at 48 hours after IL4 treatment. But at 24 hours after 
stimulation, the mRNA levels of Trem2 were not significantly different from the 
baseline Trem2 expression, consistent with a recent study published by Owen 
and colleagues showing that 24-hour IL4 treatment did not affect Trem2 
expression in primary microglia or the BV2 cell line (Owens et al., 2017), 
although they did not investigate whether longer IL4 treatment could increase 
Trem2 expression. Conclusively, IL4-induced microglial alternative activation 
is accompanied by increased Trem2 expression, but it occurs with an 
apparent delay compared with the induction of typical M2 genes. IL4 signals 
through IL4Rα that predominantly activates STAT6, which plays a central role 
in inducing M2 genes expression (Gordon and Martinez, 2010; Luzina et al., 
2012; Nelms et al., 1999). A study with Stat6-knockout mice shows that the 
presence of STAT6 is sufficient but not necessary for macrophage Trem2 
expression induction (Turnbull et al., 2006). Also considering the markedly 
delayed Trem2 mRNA increases observed in the in vitro model, I propose that 
the Trem2 up-regulation is not the direct target regulated by transcription 
factor STAT6, but is due to some other events induced at relatively later 
stages of the IL4 response, or one of the consequences of the inflammation 
suppressive effects mediated by IL4-induced inhibition of NF-κB-dependent 
transcription (Ohmori and Hamilton, 2000).    
 
Taken together, microglia constitutively express Trem2. Pro-inflammatory 
stimuli like acute infection, elevated amyloid-beta, neuronal injury, or infiltrated 
pro-inflammatory mediators from periphery could induce down-regulation of 
microglial Trem2 expression and subsequently decrease TREM2-related 
functions in microglia. This might reflect a physiological mechanism for 
microglia to adapt to the functional requirements under the inflammatory 
condition. Nevertheless, accumulated inflammation in the brain, which is often 
observed in aged brains, could cause sustained suppression of Trem2 
expression and thus an impairment of TREM2-dependent microglial functions. 
This might be one of the major mechanisms underlying TREM2 dys-function 
that contributes to sporadic AD progression with advanced age, since TREM2
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loss-of-function variants associated with increased AD risk are extremely rare 
in frequency in humans.  
 
In a previous collaborative study, we produced genome-wide gene expression 
data from different lines of mouse models mimicking either amyloid pathology 
or tau pathology in AD (Matarin et al., 2015). We identified a range of genes 
showing similar expression changing patterns in the amyloid model, with 
Trem2 as a ‘hub’ gene in the network. To analyze the potential regulating 
factors for Trem2 expression, we employed the top 50 genes in the network 
most similar to the change in Trem2 expression and searched for transcription 
factor binding sites (performed by Dr. Evan Santo and Dr. Dervis Salih). We 
found that this group of genes contained significant enrichment (p<0.01) for 
90 binding motifs for transcription factors from the TRANSFAC database 
(version February 2013; http://www.biobase.de), of which only eight 
transcription factors (E2f2, Myc, Spib, Egr3, Egr1, Spi1, E2f4 and Xbp1) were 
expressed at the highest level in microglia in the mouse brain compared to 
other cell types, according to an online database (http://www.brainrnaseq.org) 
generated by Ben Barres and colleagues (Zhang et al., 2014). Of these eight 
transcription factors, only the SPI1 binding motif was present in the promoter 
region of Trem2 (defined as 2.5 kb upstream of the transcription start site and 
0.5 kb downstream of the transcription start into the first intron; figure 6.1 A), 
which was bound by transcription factor PU.1 and also potentially by SPIB. A 
previous study also suggested TREM2 as a PU.1 target gene in the BV2 cell 
line (Satoh et al., 2014) and human monocytes (Huang et al., 2017). PU.1 is a 
key transcription factor required for myeloid cell development and functions, 
including microglia (McKercher et al., 1996). Particularly, it was found that 
Spi1 (the gene encoding PU.1) overexpression or knockdown regulated 
expression levels of many AD risk genes in the BV2 cell line, and lower 
expression of PU.1 was associated with a decreased AD risk (Huang et al., 
2017). All these thus suggest a potential role of PU.1 in Trem2 expression 
regulation. However, in my in vitro model, Spi1 expression was found to be 
up-regulated in both LPS- and IL4- treated conditions (figure 3.7 and 3.9), 
whereas Trem2 expression was divergently regulated. Especially in the LPS 
condition, Spi1 showed an over 2-fold up-regulation at all time points of 
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analysis, while Trem2 was found to be largely down-regulated, suggesting 
PU.1 may not be the key regulator of Trem2 expression in microglia. To 
investigate more specifically the role of PU.1 in Trem2 expression regulation, I 
used an RNAi strategy to knockdown Spi1 in the BV2 cell line (figure 6.1 B); 
Note, I tried to knock down Spi1 in my primary microglial model but this 
caused severe cell death, which made it impossible to collect enough samples 
for analysis. I found in the BV2 cell line that, different from the Csf1r 
expression that was strongly inhibited by Spi1 knock-down, the Trem2 
expression was not significantly changed, although there was a trend towards 
a decreased level (p=0.094; One-sample t-test). This is consistent with the 
findings by Huang and colleagues (Huang et al., 2017) that also showed 
Trem2 expression was not significantly affected by Spi1 overexpression or 
knockdown in BV2 cells. Therefore, PU.1 does not seem to play a central role 
in regulating Trem2 expression levels in microglia either in vitro or in our 
mouse models of AD.  
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Figure 6.1. PU.1 is not the key regulator for Trem2 expression in the 
BV2 cell line. (A) 50 genes (including Trem2) behaving most similarly in a 
microarray analysis with amyloid mouse models versus the wildtype 
(Matarin et al., 2015) were analyzed for potential transcription factor 
binding sites using the TRANSFAC database. There were 90 significantly 
enriched binding sites (p<0.01) for transcription factors, of which only 8 
were expressed most by microglia in the mouse brain 
(http://www.brainrnaseq.org).  Moreover, only the SPI1 binding site was 
present in the promoter region of the Trem2 gene. (B) BV2 cells were 
treated with either Spi1 siRNA or non-targeting siRNA for 48 hours, and 
analyzed for gene expression. Spi1 levels were decreased by around 90%, 
and Csf1r showed over 80% down-regulation. However, the Trem2 
expression level was not significantly affected. N=3 independent 
experiments. Data shown as Mean ± SEM. One-sample t-test; ** p<0.01, 
*** p<0.001, **** p<0.0001.   
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Microglial basal gene expression changes resulting from 
Trem2 expression deficiency, such as decreased Igf1 
expression levels 
 
The next question is how loss of TREM2 expression affects microglial 
functions. To answer this question, I first examined if acute Trem2 deficiency 
induced by RNAi influences gene expression in the primary microglia. Then 
we polarized microglia to either M1 classical or M2 alternative phenotypes to 
investigate if Trem2 deficiency alters microglial activation.  
 
To characterize the contribution of TREM2 to the normal microglial 
phenotype, I investigated the gene expressional changes in primary microglia 
with acute Trem2 knockdown in regular microglial culture conditions. I found a 
significant decrease in the expression levels of a range of microglial genes 
such as Cd68, Csf1r, Igf1, Pik3cg, and Spi1. This effect appeared subtle – 
only a 10-20% decrease of expression of those genes was observed, 
especially compared to the strong knockdown (70%) of Trem2 obtained. It 
suggests that Trem2 deficiency may not strongly impair the baseline 
microglial state but only slightly shift the microglial phenotype, and in future 
studies we would employ microarray or RNA-seq to further investigate the 
effect of Trem2 knockdown on the entire microglial transcriptome.  
 
An important point which needs to be considered here is that in vivo microglia 
receive various regulatory signals from other brain cell types such as neurons 
(e.g. CX3CL1 and CD200) to maintain the normal microglial phenotype and 
surveillance abilities, and in vitro primary microglia have been shown to 
exhibit a significantly different transcriptional signature compared to the in vivo 
microglia (Butovsky et al., 2014). Also, CSF1 (or IL34), the ligand of CSF1R 
and a key survival factor for microglia (Elmore et al., 2014), was not added to 
our regular microglial culture medium. Although the mixed-glial-conditioned 
medium used to culture isolated primary microglia might still bear some of the 
trophic factors for microglial survival, there was still increasing cell death as 
the trophic factors were consumed. Therefore, the microglia at the point of 
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analysis may not exactly represent normal ‘resting’ microglial state but act 
more like a microglial phenotype in slightly stressed conditions, and thus the 
effects of Trem2 deficiency we observed here actually reflect the implications 
of Trem2 on slightly stressed and activated microglia rather than normal 
microglia in healthy brains. It still needs further study for whether such 
phenotype shifts also happen in vivo when Trem2 expression or function is 
suppressed. A very recent paper has studied the microglial transcriptome in 
Trem2 knock-out mice and found a wide range of genes slightly but 
significantly dys-regulated, a majority of which represent functions in 
microglial mobility and chemotaxis (Mazaheri et al., 2017). However, the 
knock-out mouse model with complete TREM2 loss likely contain some 
detrimental or compensatory/homeostatic responses indirectly due to TREM2 
loss, especially during development, which may influence the estimation of 
TREM2 regulatory functions. Mice with disease-associated TREM2 variants 
knocked-in or acute Trem2 knock-down via e.g. oligonucleotide-based in vivo 
gene silencing may provide better in vivo models to study the direct regulating 
functions of TREM2 on microglia.  
 
Among the down-regulated genes I observed in the in vitro Trem2 knock-
down model, Igf1 is the most pronounced changed gene which was also 
validated with another independent Trem2 siRNA.  IGF1 is an important 
neurotrophic factor in the brain, mainly involved in neuroprotection, 
neurogenesis, synaptic plasticity maintenance, anti-inflammation and ageing 
(Fernandez and Torres-Aleman, 2012). In addition to its peripheral source 
from the liver, IGF1 is also produced locally in the brain. In general, microglia 
are the major source of IGF1 produced in the CNS whereas neurons 
constitute the main targets of IGF1 due to high expression of IGF1R, although 
it is found that IGF1 is only abundantly expressed by activated microglia 
during postnatal development, ageing or following brain injuries and plays a 
vital role in promoting neuronal survival (Fernandez and Torres-Aleman, 
2012; Kohman et al., 2012; Thored et al., 2009; Ueno et al., 2013). In the in 
vitro model, as described above that it represents a slightly stressed and 
activated microglial phenotype, it is not surprising that I observe a relatively 
high Igf1 expression in microglia. Both my findings and previous studies 
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(Arkins et al., 1995; Barrett et al., 2015; Suh et al., 2013; Wynes and Riches, 
2003) show that Igf1 expression is inhibited by pro-inflammatory stimuli and 
enhanced in M2 anti-inflammatory environments. Thus the Igf1 expression 
decrease caused by Trem2 deficiency may suggest a microglial phenotype 
shift towards M1 activation but away from M2, and a decrease of the pro-
survival role on neurons.  
 
The phenotype shift caused by Trem2 knock-down made us curious about 
how Trem2 deficiency affects microglia reactions in response to M1 pro-
inflammatory or M2 anti-inflammatory stimuli. So I polarized our in vitro model 
to either M1 or M2 activation with LPS or IL4 application. However, an 
important issue about microglial activation in vivo has to be considered 
carefully. Different from microglia polarized to M1/2 states with purified LPS or 
IL4 stimuli in vitro, microglia in vivo never receive only one single stimulus to 
govern their activation states. Instead, they are modulated by mixed cues 
including various regulatory signals from local environment (e.g. from neurons 
and astrocytes) and exposure to emerged DAMPs (disease-associated 
molecular patterns) and cytokine stimuli, leading to a mixed, dynamic and 
context-dependent microglial phenotype in vivo. It has been clear that reactive 
microglia in diseased brains demonstrate a mixed phenotype with expression 
of both M1 and M2 markers, even at the single-cell level, rather than 
completely reproduce the phenotype obtained from in vitro polarization 
studies (Kim et al., 2016; Morganti et al., 2016). Therefore, it is apparently 
inappropriate to directly apply the in vitro phenotype to our interpretation of in 
vivo microglial activation. However, I propose M1 and M2 stimuli still 
represent part of the driving factors determining the range microglia fall in of 
the entire multidimensional continuum of microglial activation. Thus, to study 
the relevance of TREM2 in regulating microglial activation, I initially used the 
polarization experiments to dissect the reaction of microglia in response to 
either M1 or M2 stimuli and investigate the effects of Trem2 deficiency in each 
direction. 
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Modestly amplified M1 pro-inflammatory activation of Trem2-
deficient primary microglia in response to LPS 
 
As discussed earlier, Trem2 expression was largely suppressed in microglia 
with LPS stimulation, suggesting inhibition of TREM2-related functions in pro-
inflammatory responses. I found that the M1 gene expression changes in 
response to LPS were not significantly different between the control group 
and the Trem2 knockdown group, which was not surprising to us as the 
Trem2 expression in the control group treated with LPS was suppressed to a 
comparable level to that in the knockdown group. However, I did observe a 
modest increase of the LPS-induced pro-inflammatory secreted marker TNFα 
at the protein level in the knockdown group compared to the control, by ELISA 
analysis of microglial supernatants. Furthermore, a cytokine array confirmed 
increased LPS-induced TNFα production (~1.5-fold) in the Trem2-knockdown 
microglia compared to the control. Previous studies using primary microglia, 
BV2 cells, or macrophage cultures have also shown that Trem2 deficiency 
results in an elevated M1 response with pro-inflammatory stimuli, as 
measured by increased inflammatory cytokine production (Gao et al., 2013; 
Takahashi et al., 2005; Turnbull et al., 2006; Zhong et al., 2015). Therefore, 
constitutive expression and function of TREM2 may play a role in restraining 
the levels of microglial pro-inflammatory responses, although the underlying 
mechanisms are still unclear. My findings do not seem to suggest a strong 
effect at the transcriptional levels, as the pro-inflammatory marker mRNA 
increases did not show significant differences between the knockdown and 
control groups. The TREM2 signaling might instead affect the proteolytic 
cleavage and secretion of pro-inflammatory cytokines, which still needs 
further investigation.   
 
Additionally, I found a range of pro-inflammatory chemokines such as CCL2, 
CCL3, CCL4, CCL5, CXCL1, CXCL13, etc. induced by LPS and showing a 
similar increasing trend to TNFα in the Trem2-knockdown microglia versus 
the control, none of which demonstrated more than a 2-fold change. Among 
all the cytokines / chemokines detected in the LPS-treated microglia by the 
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parallel proteome array, CCL5 was the factor with the highest detected signal, 
suggesting a high level of release from microglia in response to LPS, and 
particularly it showed over a 1.6-fold increase in the Trem2-knockdown group 
than the control. CCL5 (also known as ‘Regulated on activation normal T cell 
expressed and secreted’; RANTES) is a pro-inflammatory chemokine mainly 
produced by T cells and antigen-presenting cells and in the brain by microglia, 
and it is known to induce migration and homing of classical lymphoid cells 
such as T cells and monocytes (Appay and Rowland-Jones, 2001; Hu et al., 
1999). It was suggested to play an important role in CNS infiltration of T cells 
in a Parkinson’s disease mouse model (Chandra et al., 2016), and besides its 
chemo-attractant role, it was also found to amplify microglial pro-inflammatory 
responses in vitro (Skuljec et al., 2011). Furthermore, CCL2 (also known as 
‘Monocyte chemotactic protein 1’; MCP-1), a key chemokine determining 
leukocyte infiltration in injured CNS (Babcock et al., 2003; Bose and Cho, 
2013; Huang et al., 2001), was also produced around 1.6-fold higher in the 
Trem2-knockdown microglia than the control. Therefore, Trem2-deficient 
microglia, when encountering pro-inflammatory stimuli, appear to show 
stronger chemokine production involved in interactions between microglia and 
peripheral immune cells. In the context of brain injury, this might provide a 
promoting role in infiltration of peripheral immune cells.  
 
 
Attenuated M2 alternative activation of Trem2-deficient 
microglia in response to IL4  
 
The M2 alternative activation induced by IL4 treatment seemed to be affected 
more prominently by Trem2-deficiency.  I found significantly reduced Arg1 up-
regulation and a trend of decreased Tgfb1 up-regulation in Trem2-knockdown 
microglia with IL4. ARG1 and TGFβ1 are both important M2 markers. ARG1 
(Arginase-1) in macrophages mainly functions as an enzyme to hydrolyze 
arginine to produce ornithine, which on one side promotes tissue repair 
through generation of polyamines and collagens and on the other side 
reduces nitric oxide production from iNOS through limiting intracellular 
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arginine availability (Yang and Ming, 2014). TGFβ1 promotes an inflammation 
suppressive function in microglia and enhances IL4-induced M2 activation of 
microglia through a MAPK-dependent pathway (Basu et al., 2002; Herrera-
Molina and von Bernhardi, 2005; Suzumura et al., 1993; Zhou et al., 2012). 
Importantly, TGFβ1 has been recently found to be a key factor to retain a 
normal ‘resting’ microglial signature in vivo (Butovsky et al., 2014). Our 
findings suggest an attenuated M2 phenotype expression in Trem2-
knockdown microglia, although Trem2-deficiency does not seem to 
completely block the IL4-induced expression of M2 markers. I thus propose 
TREM2 signaling may function in parallel to facilitate IL4-induced transcription 
changes. TREM2 signals through DAP12 or DAP10, which recruits SYK and 
initiates a cascade of downstream signaling events, such as PI3K activation, 
MAPK activation, and calcium mobilization (as discussed in Chapter 1). IL4 
signaling mainly regulates M2 gene transcription through STAT6 activation in 
macrophages, but it also recruits IRS-1/2 to activate the PI3K pathway that is 
required for STAT6-dependent transcription changes (Gordon and Martinez, 
2010; Rauh et al., 2005; Weisser et al., 2011). Additionally, p38 MAPK has 
also been suggested to be involved in IL4-induced M2 phenotype expression 
in macrophages (Jimenez-Garcia et al., 2015). Therefore, the PI3K and 
MAPK pathways activated by TREM2 signaling might provide a supportive 
intracellular environment to enhance the STAT6-dependent gene transcription 
induced by IL4, which is worth following up to confirm. However, the PI3K/Akt 
pathway, in the context of M2 activation, could be activated by multiple 
signaling pathways, such as direct IL4-IRS1/2 recruitment and IGF1 signaling 
as well, which is also up-regulated and suggested to contribute to IL4-induced 
M2 activation. All these pathways might coordinate together, and probably 
temporarily, to control the microglial anti-inflammatory phenotype.  
 
Similar to LPS-treated microglia, I also observed an increase in the release of 
various cytokines / chemokines from the IL4-treated Trem2-knockdown 
microglia compared to the IL4-treated control microglia. Most of the altered 
chemokines overlapped with those found in LPS-treated cells, such as CCL5, 
CCL2, CXCL1, TIMP-1, CXCL12, CXCL10, etc., although the absolute 
detected signal levels were lower than those from LPS-treated cells. However, 
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the fold change was much higher in the IL4 conditions, further suggesting a 
stronger effect of Trem2-deficiency on IL4 responses. The most prominently 
altered chemokine was CXCL1 (keratinocyte-derived chemokine; KC), which 
showed a 6-fold higher level in the IL4-treated knockdown group than the IL4-
treated control group. Notably, in the LPS conditions, its release was also 
higher (around 1.5-fold of the control) in the Trem2-knockdown microglia. 
CXCL1 is a chemokine mainly expressed by macrophages, neutrophils and 
epithelial cells, and known as a chemoattractant for leukocyte recruitment 
(Baggiolini, 1998; Haskill et al., 1990). Previous studies have also suggested 
its potential relevance with AD. For example, its receptor CXCR2 was found 
to be expressed by hippocampal neurons and up-regulated in the neurites 
surrounding Aβ plaques in AD (Horuk et al., 1997). A study suggested that 
CXCL1 could trigger tau hyper-phosphorylation in mouse primary neurons 
through the ERK1/2 and PI3K pathway (Xia and Hyman, 2002). Also, CXCL1 
could activate astrocytes and promote their cytokine and chemokine 
production (Luo et al., 2000). However, as endothelial cells rather than 
microglia are the major source of CXCL1 in the brain, it is still not clear 
whether Trem2-deficiency-induced microglial CXCL1 production increase is of 
any obvious functional relevance in the brain homeostasis and AD 
pathogenesis.  
 
Overall so far, I have shown that acutely induced Trem2 deficiency results in a 
slight but significant microglial gene expressional change, which might be 
associated with a more pro-inflammatory state of microglia and lead to less 
neuroprotective functions. With LPS stimulation, Trem2 deficiency amplifies 
the pro-inflammatory response of microglia, albeit only modestly. With the IL4 
application, however, microglial anti-inflammatory responses are considerably 
affected at least at the transcriptional levels. Additionally, Trem2 deficiency 
leads to an enhanced chemokine secretion in both M1 and M2 conditions, 
which might suggest an over-reactive microglial response and potentially 
more infiltration of peripheral immune cells into the CNS.  
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Divergent Trem2 expression and microglial gene expression 
profile between amyloid mice and tau mice 
 
To characterize the differences in the microglial activation at different 
pathology stages of AD in vivo, I employed two lines of transgenic mouse 
models mimicking the amyloid pathology and the tau pathology respectively. I 
examined the microglial gene expression in the hippocampus of different aged 
mice to allow us to assess changes associated with different stages of 
disease. This allows us to investigate microglial reaction in response to 
different aspects of AD pathology, that being rising amyloid-beta and plaque 
deposition in APP/PSEN1 mice versus rising hyper-phosphorylated tau and 
neurofibrillary tangles in TauD35 mice. I identified three major stages in 
pathology development to analyze the similarities and differences between 
the two lines of mouse model, especially between the HO-APP/PSEN1 and 
the high-copy TauD35 mice. First, at 4-8 months of age, when the 
APP/PSEN1 mice started to develop mature dense-core Aβ plaque deposition 
in the hippocampus, with the heterozygous showing a slower rate than the 
homozygous, we observed that the expression levels of microglial genes such 
as Aif1, Cd68, and Trem2 started to increase. In contrast, the TauD35 mice 
microglial genes still showed comparable expression levels to wildtype mice 
at this stage when the high-TAU model demonstrated a significant degree of 
phosphorylated tau in the hippocampus and started to develop neurofibrillary 
tangles.  Secondly, at 12 months of age, when both APP/PSEN1 mice and 
high-TAU mice exhibited a relatively heavy load of Aβ plaques or tangles in 
the hippocampus, the amyloid model showed further increased expression of 
these microglial genes, and the tau model just started to show the up-
regulation. Thirdly, at 18 months, the HO-APP/PSEN1 hippocampus was 
heavily covered by plaques and the high-TAU showed a significant neuronal 
loss. Not surprisingly, microglial genes expression further increased in both 
models. I also observed a significantly increased expression with age in the 
pro-inflammatory genes Tnf and Il1b and the anti-inflammatory gene Tgfb1 in 
both models, but in general no overtly pro- or anti- inflammatory phenotype 
developed. It seemed that the amyloid model showed increasing microglial 
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gene expression following the progressing amyloid deposition; while in the tau 
mice there was a delay in the microglial gene response compared to the 
tangle development. One important point here is that the cDNA samples were 
generated from the whole hippocampus including all cell types, so the 
microglial gene expression changes might be partially due to an expansion of 
the microglial population. Also that some more subtle but significant microglial 
gene expression changes might be masked by using a whole hippocampal 
homogenate of mixed cell types. 
 
Trem2 expression showed up-regulation along with pathology progression in 
both models, but the expression levels were consistently lower in the tau 
model than in the amyloid model. To further characterize the relative Trem2 
expression in microglia, we used Aif1 as a reference to normalize it, to provide 
a measure of the average Trem2 expression in the microglial population. I 
found, interestingly, the relative Trem2 levels were getting significantly higher 
as amyloid pathology developed, whereas the tau mice only showed 
comparable relative Trem2 expression levels to wildtype mice even at the late 
stage with severe neuronal loss. Although the Trem2/Aif1 ratio does not 
exactly represent the Trem2 expression level per microglia because of 
heterogeneity of the microglial population and potential Aif1 expression 
differences, it still provides us with some information on the average Trem2 
expression in microglia. Moreover, as we described in our previous paper 
(Matarin et al., 2015), network analysis of the gene expression changes in 
these two lines of mouse models suggested Trem2 as a hub gene with 
extremely high connectivity with other genes in the amyloid model, but not in 
the tau model. Therefore, we propose that in response to Aβ deposition 
microglial Trem2 expression is up-regulated starting from early stages of 
pathology, which may play an important role in regulating the microglial 
activation. However, in the tau model, Trem2 does not seem to be critically 
involved in regulation of microglial activation in response to tangles, and its 
exact expression level is not convincingly up-regulated despite an expansion 
of the entire microglial population. In a recently published study (Keren-Shaul 
et al., 2017), it was suggested that Trem2 expression determined 
development of a protective disease-associated microglial activation 
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phenotype associated with plaques in the 5XFAD mouse model, further 
suggesting the central role of TREM2 in regulating robust microglial activation 
in response to amyloid pathology development.  
 
To further confirm the difference in the microglial gene expression between 
the amyloid model and the tau model, we then employed the gene expression 
database (www.mouseac.org) generated in our previous study (Matarin et al., 
2015) and presented further analysis of the microglial genes in the 18-month 
HO-APP/PSEN1 and high-TAU mice, both at a late stage of pathology 
development. Genes expressed most abundantly in microglia were identified 
using the online database generated by Ben Barres and colleagues showing 
gene expression changes between different cell types of the mouse brain 
(http://www.brainrnaseq.org; Zhang et al., 2014). We then identified genes 
with more than 20% increases or decreases comparing wildtype to the 
amyloid or the tau mice (with p<0.01). We found considerable differences in 
the microglial genes both up-regulated and down-regulated between these 
two models (figure 6.2). This comparison further suggests a different 
microglial phenotype induced in the amyloid model versus the tau model.  
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In brief, I have revealed the microglial gene expression reaction to amyloid 
versus tau pathology in mouse models, and particularly suggested a TREM2-
involved early microglial activation in response to amyloid deposition. Such 
robust microglial activation associated with amyloid pathology development 
does not show an obvious pro-inflammatory state, and probably protects 
against further AD-related pathology progression and the transition to late 
stages of the disease, as the amyloid model does not show fully developed 
AD (tau tangles and neuronal death). However, the situation is different in 
human brains. The mouse models are always kept in a well-controlled 
pathogen-free environment, and so lacking a variety of modifiable 
environmental risk factors that humans are normally exposed to during 
ageing, such as type 2 diabetes, vascular diseases, smoking, and obesity. 
These factors are usually associated with an increased systemic inflammatory 
state, which could ‘prime’ microglia in the brain and cause exaggerated or 
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Figure 6.2. Genes with expression levels changed >20% in the HO-APP/PSEN1 mice 
and the high-TAU mice at 18 months compared to wildtype mice. Venn diagrams 
depicting the overlap between genes increased or decreased >20% (ANOVA, p<0.01) 
within the hippocampus of the HO-APP/PSEN1 and high-TAU animals at 18 months. 
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dys-regulated reactions to emerging AD-related pathology (Cunningham et 
al., 2009; Perry et al., 2007; Perry and Holmes, 2014). Such dys-regulated 
immune reactions might be a critical component in AD contributing to the 
progression from the stage of Aβ elevation to that of tau pathology and 
neurodegeneration.  
 
 
Histology differences in microglia between amyloid and tau 
models 
 
I then performed immunohistochemistry to further investigate the expansion 
and activation of the microglial population in the amyloid compared to the tau 
models. In the 4-month HO-APP/PSEN1 mice, when mature plaques just 
started to develop, I did not observe a significant difference in the overall 
microglia number in the hippocampus compared to the wildtype mice. But that 
could be partially due to a small sample size of the 4-month HO-APP/PSEN1 
group. The mean microglia number of this group was actually around 1.4-fold 
of the wildtype in dentate gyrus and around 2-fold in CA1 region, suggesting 
microglia may potentially start to proliferate at this stage as amyloid plaques 
begin to be deposited. In future work we might be able to determine if this 
early proliferation is significant. I did find a highly increased number of total 
microglia and CD68-positive microglia in the hippocampus of the HO-
APP/PSEN1 model at 12 months, when they developed a relatively heavy 
plaque load. For the tau model, I did not observe any significant increase of 
microglia in the hippocampus at the pre-tangle (4-month low- and high-TAU) 
or early tangle (12-month low-TAU) stages, whereas in 12-month high-TAU 
mice, both total microglia and CD68-positive microglia showed significant 
increases compared to the wildtype. Additionally, I observed a slightly 
increased percentage of CD68-positive microglia in the entire microglial 
population in the hippocampus of 12-month high-TAU mice, while in the HO-
APP/PSEN1 mice this proportion did not show a significant difference from 
that in the wildtype. Interestingly, despite the genotype, I also observed an 
increase of the proportion of CD68-positive microglia with age. The increased 
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CD68 proportion possibly suggests an increased proportion of microglia with 
high phagocytic activity.   
 
A pronounced difference in the microglia between the amyloid and tau models 
I observed was the distribution of microglia in the hippocampal CA1 region. I 
found a particularly increased microglia density in the SLM layer (stratum 
lacunosum-moleculare) of CA1 region in the 12-month high-TAU mice, 
whereas in the APP/PSEN1 mice the density of microglia increased almost 
equally among all different layers of CA1. Moreover, the MHC-II positive 
microglia also tended to accumulate in this SLM region of the tau mice, 
suggesting a highly activated subgroup of microglia in this region. This is 
interesting because the SP (stratum pyramidale) layer, rather than the SLM 
layer, is the region with CA1 pyramidal neuronal cell bodies where tau tangles 
accumulate, which did not show much changes compared with the wildtype. 
The SLM is where the perforant pathway fibers from the entorhinal cortex 
form synapses with the CA1 pyramidal neurons. In human AD, tau pathology 
tends to progress from the entorhinal cortex to the hippocampus (Braak and 
Braak, 1991, 1997), suggesting a higher vulnerability of entorhinal neurons 
and a potential involvement of the synaptic pathways between entorhinal 
cortex and hippocampus in tauopathy progression. Trans-synaptic tau 
propagation from entorhinal neurons has been implicated with the tau mice 
harbouring human-tau restricted to the entorhinal cortex but showing 
detectable tau aggregates downstream in the synaptic circuit (de Calignon et 
al., 2012; Harris et al., 2012; Liu et al., 2012). Further research reveals that 
neuronal activity stimulates tau protein release from neurons (Pooler et al., 
2013; Wu et al., 2016; Yamada et al., 2014). Moreover, it has been postulated 
that microglia take up tau proteins released from neurons and play a role in 
trans-neuronal tau propagation, suggesting they actively react to neuronally 
released tau (Asai et al., 2015; Wang et al., 2017). So it is possible that there 
is a higher level of released tau proteins from the perforant fibers in the SLM 
region, which drives microglial accumulation and activation here. Another 
possible cause might be potential neurite or synaptic damage in this region. 
The CA1 pyramidal neurons project distal apical dendrites to the SLM region, 
and 12-month high-TAU mice show a high load of tangles in the CA1 
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pyramidal neurons, which could result in degeneration of spines or dendrites. 
A few studies have shown dendritic dystrophy of cortical or hippocampal 
neurons in the rTg4510 tau (P301L) mice or the AAV-tau (P301L)-transfected 
mice, which is particularly pronounced in the distal apical parts (Crimins et al., 
2012; Jaworski et al., 2011). Previous work in our lab (Joel 2015, PhD 
dissertation) has not found significant electrophysiological changes in the 
Schaffer collateral pathways in CA1 of the tau model at this stage, but we 
have not investigated the perforant pathway yet; except a significantly 
increased membrane potential in the CA1 pyramidal neurons, suggesting 
reduced ion channel opening that might be due to a dendritic regression 
induced membrane surface decrease.  
 
 
Lack of strong MHC-II induction in the amyloid model compared to the 
tau model or human AD  
 
MHC-II (Major Histocompatibility Class II) is a range of cell surface receptors 
involved in antigen presentation and the adaptive immune response 
elicitation, which is usually associated with up-regulated inflammation. I only 
found scattered MHC-II positive cells in the cortex and hippocampus of the 
APP/PSEN1 mice with medium to heavy plaque loads, with a considerable 
variability in the number of the MHC-II positive cells between different mice. 
All MHC-II positive cells were also IBA1-positive, indicating they are 
predominantly microglia. This MHC-II positive subgroup seemed only to 
constitute a very small proportion of microglia in the APP/PSEN1 mice at this 
stage with a highly expanded microglial population, whereas the tau model 
seemed to show more considerable MHC-II positive microglia. Surprisingly, I 
did not observe any MHC-II positive microglia in the brain parenchyma of 
wildtype mice at any age groups (4, 12, 24, and 30 months). A previous study 
with a different APP/PS1 mouse model and a different MHC-II antibody also 
found that the number of MHC-II positive microglia only increased at late 
stages of Aβ pathology and showed a high inter-animal variability with no 
obvious correlation to the plaque amount (Gordon et al., 2002). This is 
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contrary to the findings in human patients. Early AD pathological reports 
(Itagaki et al., 1989; McGeer et al., 1987; Perlmutter et al., 1992; Rogers et 
al., 1988; Styren et al., 1990) show that AD patients exhibit highly increased 
MHC-II positive microglia, most clustering around plaques (and tangles, but 
not always). Additionally, they find scattered MHC-II immunoreactivity in the 
white matter of the non-demented control people, with a positive correlation 
with age (Perlmutter et al., 1992; Rogers et al., 1988; Styren et al., 1990). 
This difference between human and mice might be partially due to species 
differences, and/or different sensitivity of the antibodies. But another 
possibility perhaps is that the lack of ‘microglial priming’ factors in the mouse 
model compared to elderly people, as we discussed earlier, results in a robust 
and less-detrimental microglial phenotype represented by a relatively low level 
of MHC-II induction in response to Aβ pathology, while in human AD, for 
some reason the microglia fail to react appropriately but induce a more pro-
inflammatory phenotype with high MHC-II expression, which might be an 
important component in downstream progression of the Aβ pathology. 
Particularly, an early study found that a group of non-demented elderly people 
showed a significantly lower number of MHC-II positive microglia compared to 
a group of age-matched AD patients despite the plaque load being 
comparable (Lue et al., 1996). Also, in a post-mortem study, researchers 
found that MHC-II levels in AD brains showed a negative relationship with the 
MMSE scores and a positive relationship with neuritic plaque and 
neurofibrillary tangle load, whereas in non-demented people the MHC-II levels 
only showed an insignificant or negative relationship with AD pathology, 
except a positive relationship with the diffuse plaque load (Minett et al., 2016). 
As we suggest Trem2 up-regulation in the amyloid mouse model plays a 
central role in the microglial activation, it would be interesting to investigate 
whether microglial Trem2 expression / function is to some extent correlated 
with the MHCII levels, and also whether the MHC-II levels are different in 
human AD with TREM2 risk variants.  
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Conclusions 
 
In this study, I established an in vitro primary microglia model that could be 
used to test the mechanism of action of the newly discovered microglial 
GWAS hits, which was validated here with acute Trem2 knock-down. I found 
that TREM2 played an important role in microglial phenotype regulation. 
Specifically, besides validating phagocytosis impairment, acutely induced 
Trem2 deficiency resulted in slight but significant microglial gene expression 
changes, suggesting a phenotype shift towards a pro-inflammatory state and 
away from an anti-inflammatory and neurotrophic state. Trem2 deficiency in 
microglia modestly amplified the M1 classical activation in response to the 
pro-inflammatory stimulus LPS, and substantially impaired the M2 alternative 
activation in response to IL4. I also found that Trem2 suppression led to 
enhanced expression of chemoattractants, especially for peripheral immune 
cells, perhaps suggesting an exaggerated microglial phenotype in response to 
stimuli and potentially increased driving force for leukocyte infiltration in the 
context of injured brains. Additionally, with respect to the regulation of Trem2 
expression, I found that a pro-inflammatory environment inhibited Trem2 
expression while anti-inflammatory cues enhanced Trem2 expression, 
suggesting that TREM2 is functional in anti-inflammatory situations. 
 
In a line of an amyloid mouse model, I observed an up-regulation of Trem2 
expression relative to the number of microglia from early stages of amyloid 
pathology, which was not found in the tau model that showed a more pro-
inflammatory microglial phenotype. Together with our previous network 
analysis (Matarin et al., 2015), my findings suggest a potentially central role of 
Trem2 up-regulation in coordinating a robust and balanced microglial reaction 
to amyloid pathology. Since we do not observe a fully developed AD 
pathology in the amyloid model (lacking tau tangles and neuronal death), I 
propose that enhanced TREM2 expression / function and lack of other 
environment ‘microglial priming’ factors experienced by humans outside of a 
mouse facility lead to a robust protective microglial activation (with low MHCII 
induction) accompanying the amyloid pathology, which prevents further 
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downstream development of AD. However, the Trem2 inhibition due to the 
pro-inflammatory stimuli (as suggested by my in vitro work) might be 
prolonged in the context of human aged brains where various environmental 
risk factors could increase the baseline inflammation levels. Then such Trem2 
inhibition may impact upon microglial reactions to dys-regulated Aβ 
metabolism, which could be one of the microglial mechanisms contributing to 
AD pathogenesis, especially at the post- Aβ and pre-tangle stages.   
 
It would provide great insights for drug discovery if we could expand the work 
described here showing that microglia respond differently in amyloid versus 
tau pathology environments by identifying the genetic network differences in 
the microglial populations to enable appropriate modulation of microglia with 
pharmacology. Also, in future work, it would be interesting to further study the 
role of Aβ-induced microglial activation in the link of Aβ driving the tau 
pathology in AD progression, and also the contribution of tau-induced 
microglial activation back to the Aβ pathology.  
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